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Report on the risk assessment 
of 5-(2-aminopropyl)indole in the framework  
of the Council Decision on new 
psychoactive substances
About this series
EMCDDA Risk Assessments are publications 
examining the health and social risks of 
individual new psychoactive substances.
The Risk Assessment Report consists of an 
analysis of the scientific and law enforcement 
information available on the new psychoactive 
substance under scrutiny and the implications 
of placing it under control. It is the outcome of 
a meeting convened under the auspices of the 
EMCDDA Scientific Committee.
This process is part of a three-step procedure 
involving information exchange/early warning, 
risk assessment and decision-making in the 
framework of the Council Decision  
2005/387/JHA.
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I Foreword
It is with great pleasure that I present this comprehensive publication, which contains the 
data and findings of the risk assessment on the new psychoactive substance, 
5-(2-aminopropyl)indole, that was conducted by the Scientific Committee of the EMCDDA.
Concerns over the availability and use of this stimulant drug in the European Union led to 
an assessment of the health and social risks posed by the substance, and, consequently, 
its control across the EU Member States. The decision of the Council of the European 
Union to control 5-(2-aminopropyl)indole, on the initiative of the European Commission, 
marks the final stage in the three-step process set up by Council Decision 2005/387/JHA 
on the information exchange, risk assessment and control of new psychoactive 
substances, which allows the European Union to respond to potentially threatening new 
psychoactive substances.
Only a few years ago, ‘new drugs’ such as 5-(2-aminopropyl)indole were generally regarded 
as being of limited significance to drug policy. The continued growth of this market — 
particularly the ‘legal highs’ phenomenon — has seen the issue develop into an 
increasingly complex policy challenge that is now of major international concern. This 
growth has been driven partly by entrepreneurs who have exploited gaps in drug regulation 
and fuelled by the increasingly globalised and interconnected world in which we live. The 
ability to search the online back catalogue of pharmaceutical and medical research 
literature in order to identify substances whose psychoactive potential may make them 
attractive, get them bulk produced by commercial chemical companies based in China and 
India, rapidly distribute them across the globe using courier services, and then sell them 
on an open ‘legal highs’ market — in head shops, convenience stores, fuelling stations, and 
the Internet — is now beginning to have an impact on local, national, regional and 
international drug markets. These developments have led to the unprecedented rise in the 
number, type and availability of new drugs both in Europe and increasingly elsewhere.
In many ways 5-(2-aminopropyl)indole serves as a useful case study of these 
developments and highlights the essential role and interconnected way that multi-
disciplinary early-warning systems at the national and EU level ensure that stakeholders 
have access to timely evidence-based and authoritative information on new drugs and 
trends in their use, helping to ensure a rapid and appropriate response to individual and 
public health needs.
Information on toxicity — particularly non-fatal intoxications and deaths — plays a crucial 
role in identifying, understanding and monitoring the health and social harms caused by 
new psychoactive substances. 5-(2-Aminopropyl)indole was a ‘new drug’, in fact a very 
new drug. Within a few months of apparently being sold for the first time on the ‘legal 
highs’ market, including through online shops, deaths associated with its use were being 
reported, ultimately reaching 24 at the time of the risk assessment. Here the EU early-
warning system played a key role in the response to this substance by ensuring 
information was disseminated to forensic chemistry and toxicology laboratories so that 
they could identify the substance unambiguously as well as the early identification — and 
reporting — of non-fatal intoxications and deaths associated with the substance. Indeed, 
strengthening the toxicovigilance component of the EU early-warning system is likely to 
repay substantial dividends both at the national and EU level in terms of allowing the active 
and systematic detection, assessment, understanding, monitoring, minimisation and 
prevention of toxicity caused by new drugs.
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Scientific Committee of the EMCDDA, the EU Member States experts, the European 
Commission, Europol, the European Medicines Agency and the EMCDDA who participated 
in the formal risk assessment meeting, which took place on 11 April 2013 at the EMCDDA 
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clear support to political decision making. As ever, none of this would have been possible 
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I Introduction
The huge growth of the ‘legal highs’ phenomenon over the past few years that followed the 
appearance of BZP and mephedrone has taken many in the drug field by surprise. Since 
2010 more than 200 new psychoactive substances, most of which are sold as ‘legal highs’, 
have been notified to the EU early-warning system. This coupled to their growing diversity, 
availability and use presents a significant challenge for public health and the related policy 
responses in Europe. Essential to responding to this challenge are the risk assessments 
conducted by the Scientific Committee of the EMCDDA which continue to play a vital role 
in providing evidence-based analysis to decision makers in the European Union and 
Member States. These, in turn, are underpinned by information provided by the EU 
early-warning system.
Within the space of a few months the Scientific Committee has conducted risk 
assessments on two very different new psychoactive substances — 
4-methylamphetamine and 5-(2-aminopropyl)indole — both of which are associated with 
serious acute toxicity including deaths. However, while in the case of 
4-methylamphetamine some analogies could be drawn with amphetamine, the risk 
assessment of 5-(2-aminopropyl)indole was particularly difficult given the lack of previous 
experience with such a type of substance and the short time period between its 
emergence and reports of deaths associated with its use.
The case of 5-(2-aminopropyl)indole highlights once again the important role that the EU 
early-warning system plays in Europe. Critical here was its ability to detect signals of harm 
and disseminate emerging information on the drug. This included analytical data that 
allowed forensic and toxicology laboratories to distinguish between 5-(2-aminopropyl)
indole and α-methyltryptamine as well as information related to acute toxicity and deaths. 
In a little over eight months from when the substance appears to have first been sold, more 
than 20 deaths had been reported in four Member States.
For many new psychoactive substances that have emerged on the European drug market, 
little is known about their pharmacology and toxicology. This information is required in 
order to assess the properties of a drug, including its mechanism of action, potential for 
acute and chronic toxicity, as well as abuse liability and dependence-producing potential. I 
am pleased to note that for this risk assessment, the EMCDDA made it possible to conduct 
a study that examined the in vitro effects of 5-(2-aminopropyl)indole on monoamine 
oxidase inhibition, thus furthering our understanding of the pharmacology and toxicology 
of this drug. The importance of undertaking such studies in order to support the risk 
assessment process conducted by the Scientific Committee is clear.
The absence of information and research findings has been a challenge for all risk 
assessments conducted by the Scientific Committee. Therefore, the risk assessment 
conclusions are inevitably based on partial knowledge and, consequently, are tentative. 
Many of the questions posed by the lack of evidence on the health and social effect of 
5-(2-aminopropyl)indole could be answered by further research. Areas where additional 
information would be useful include studies on: receptor binding and functional activity; 
metabolic pathways; behavioural effects; clinical patterns of acute and chronic toxicity in 
humans; potential interactions with other substances (in particular those that affect the 
monoaminergic system); the dependence and abuse potential; and the social risks 
associated with its use. In addition to that both intended and unintended consequences of 
a decision to control 5-(2-aminopropyl)indole should be considered, as outlined in the 
present report.
RISK ASSESSMENTS I 5-(2-Aminopropyl)indole (5-IT)
6 / 50
Introduction
Despite the challenges, the risk assessment exercise under Council Decision 2005/387/
JHA remains a unique element of the European action on new drugs and constitutes an 
important instrument to support decision-making at the level of the European Union. It can 
also be viewed as a useful mechanism to provide added value and support to national 
efforts in this area, and may serve as a good example of an evidence-based approach to 
sensitive policy issues.
Finally, I would like to thank all our colleagues from the extended Scientific Committee for 
sharing their knowledge and insights that contributed to a stimulating and productive 
discussion. Also, I would like to express my appreciation to the external experts and to the 
EMCDDA staff who worked hard before, during, and after the meeting to prepare and 
finalise the reports. I hope that these combined efforts will be appreciated by those to 
whom this report is addressed.
Dr Marina Davoli
Chair of the Scientific Committee of the EMCDDA
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I EMCDDA actions on monitoring and responding to new drugs
The EMCDDA has been assigned a key role in the detection and assessment of new drugs 
in the European Union under the terms of a Council Decision 2005/387/JHA on the 
information exchange, risk-assessment and control of new psychoactive substances. It 
establishes a mechanism for the rapid exchange of information on new psychoactive 
substances and provides for an assessment of the risks associated with them in order to 
permit the measures applicable in the Member States for the control of narcotic and 
psychotropic substances to be applied also to new psychoactive substances.
The three-step process involves information exchange/early warning, risk assessment and 
decision-making (see below). More detailed information can be found in the section ‘Action 
on new drugs’ of the EMCDDA’s website:  
www.emcdda.europa.eu/activities/action-on-new-drugs
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, 
risk-assessment and control of new psychoactive substances
I. Information exchange
Early-warning system (EWS) EMCDDA–Europol Joint Reports
III. Decision-making Council Decisions on control
II. Risk assessment EMCDDA Risk Assessments
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I  EMCDDA–Europol Joint Report on 5-(2-aminopropyl)indole: a summary
EMCDDA–Europol Joint Report on a new psychoactive substance: 
5-(2-aminopropyl)indole — in accordance with Article 5 of Council Decision 
2005/387/JHA on the information exchange, risk assessment and control of new 
psychoactive substances
At the end of September 2012, the EMCDDA and Europol examined the available 
information on a new psychoactive substance, 5-(2-aminopropyl)indole, through a joint 
assessment based upon the following criteria: (1) the amount of the material seized; (2) 
evidence of organised crime involvement; (3) evidence of international trafficking; (4) 
analogy with better-studied compounds; (5) evidence of the potential for further (rapid) 
spread; and (6) evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information available on 5-(2-aminopropyl)
indole satisfies the above criteria. The two organisations therefore concluded that 
sufficient information has been accumulated to merit the production of a Joint Report on 
5-(2-aminopropyl)indole as stipulated by Article 5.1 of the Decision. Accordingly, the Reitox 
NFPs, the Europol National Units (ENUs), the EMA and the World Health Organization 
(WHO) were formally asked to provide the relevant information within six weeks from the 
date of the request, i.e. by 14 November 2012.
The resulting Joint Report on 5-(2-aminopropyl)indole was submitted to the Council, the 
Commission and the EMA on 13 December 2012. The report concluded that the health 
and social risks, caused by the use of, the manufacture of, and traffic in 5-(2-aminopropyl)
indole, as well as the involvement of organised crime and possible consequences of 
control measures, could be thoroughly assessed through a risk assessment procedure as 
foreseen by Article 6 of Council Decision 2005/387/JHA.
The full text of the Joint Report can be found at:
www.emcdda.europa.eu/publications/joint-reports/5-IT
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new psychoactive substances so that, if necessary, control 
measures can be applied for narcotic and psychotropic 
substances in the Member States (4). 
There is information that suggests that the new psychoactive 
substance 5-(2-aminopropyl)indole first appeared on the drug 
market in Europe in late 2011. It was formally notified to the 
EU early-warning system for the first time in June 2012. It has 
been associated with fatalities and non-fatal intoxications in 
four Member States. In response to this, and in compliance 
with the provisions of Article 5 of the Council Decision, on 12 
December 2012, the EMCDDA and Europol submitted to the 
Council, the Commission and the European Medicines Agency 
(EMA) a Joint Report on the new psychoactive substance 
5-(2-aminopropyl)indole (5). Taking into account the 
conclusion of the Joint Report and in accordance with Article 
6 of the Council Decision, on 24 January 2013 the Council 
formally requested that ‘the risk assessment should be carried 
out by the extended Scientific Committee of the EMCDDA and 
be submitted to the Commission and the Council within 
twelve weeks from the date of this notification’.
In accordance with Article 6.2, the meeting to assess the risks 
of 5-(2-aminopropyl)indole was convened under the auspices 
of the Scientific Committee of the EMCDDA with the 
participation of three additional experts designated by the 
Director of the EMCDDA, acting on the advice of the 
Chairperson of the Scientific Committee, chosen from a panel 
proposed by Member States and approved by the 
Management Board of the EMCDDA. The additional experts 
were from scientific fields that were either not represented or 
not sufficiently represented on the Scientific Committee, and 
whose contribution was necessary for a balanced and 
adequate assessment of the possible risks of 
5-(2-aminopropyl)indole, including health and social risks. 
Furthermore, one expert from the Commission, one expert 
from Europol and one expert from the EMA participated in the 
(4)  In compliance with the provisions of the 1961 United Nations Single 
Convention on Narcotic Drugs and the 1971 United Nations Convention on 
Psychotropic Substances.
(5)  EMCDDA and Europol (2012), EMCDDA–Europol Joint Report on a new 
psychoactive substance, 5-(2-aminopropyl)indole, EMCDDA, Lisbon. Available 
at: www.emcdda.europa.eu/publications/joint-reports/5-IT
I Introduction
This Risk Assessment Report presents the summary findings 
and the conclusions of the risk assessment carried out by the 
extended Scientific Committee of the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) on the new 
psychoactive substance 5-(2-aminopropyl)indole. The report 
has been prepared and drafted in accordance with the 
conceptual framework and the procedure set out in the Risk 
assessment of new psychoactive substances: Operating 
guidelines (1). It is written as a stand-alone document that 
presents a summary of the information considered during the 
detailed analysis of the scientific and law enforcement data 
available at this time. The conclusion section of the report 
summarises the main issues addressed and reflects the 
opinions held by the members of the Committee. A more 
detailed Technical report on 5-(2-aminopropyl)indole is 
annexed to this report (Annex 1).
The risk assessment has been undertaken in compliance with 
Article 6 of Council Decision 2005/387/JHA of 10 May 2005 
on the information exchange, risk assessment and control of 
new psychoactive substances (2) (the ‘Council Decision’). The 
Council Decision establishes a mechanism for the rapid 
exchange of information on new psychoactive substances that 
may pose public health and social threats, including the 
involvement of organised crime. Thus, it allows the institutions 
of the European Union and the Member States to act on all 
new narcotic and psychotropic substances (3) that appear on 
the European Union drug market. The Council Decision also 
provides for an assessment of the risks associated with these 
(1)  EMCDDA (2010), Risk assessment of new psychoactive substances: 
Operating guidelines, Publications Office of the European Union, 
Luxembourg. Available at: www.emcdda.europa.eu/html.cfm/
index100978EN.html
(2)  OJ L 127, 20.5.2005, p. 32.
(3)  According to the definition provided by the Council Decision, a ‘new 
psychoactive substance’ means a new narcotic drug or a new psychotropic 
drug in pure form or in a preparation; ‘new narcotic drug’ means a substance 
in pure form or in a preparation that has not been scheduled under the 1961 
United Nations Single Convention on Narcotic Drugs, and that may pose a 
threat to public health comparable to the substances listed in Schedule I, II or 
IV; ‘new psychotropic drug’ means a substance in pure form or in a 
preparation that has not been scheduled under the 1971 United Nations 
Convention on Psychotropic Substances, and that may pose a threat to public 
health comparable to the substances listed in Schedule I, II, III or IV.
Risk Assessment Report of  
a new psychoactive substance:  
5-(2-aminopropyl)indole (5-IT)
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suggests that 5-(2-aminopropyl)indole has stimulant effects 
and possible hallucinogenic effects.
The systematic (International Union of Pure and Applied 
Chemistry, IUPAC) name of 5-(2-aminopropyl)indole is 
1-(1H-indol-5-yl)propan-2-amine. Other names are used and 
are listed in Annex 1. A common abbreviation used for 
5-(2-aminopropyl)indole is 5-IT. Hereinafter, this abbreviation 
will be used interchangeably with 5-(2-aminopropyl)indole. 
The molecular structure, molecular formula and molecular 
weight, as well as the monoisotopic mass are shown below. 
Aside from AMT (at position 3-) and N-methyltryptamine 
(NMT), there are four other possible isomers where the 
2-aminopropyl chain is attached at positions 2-, 4-, 6- and 7- 
respectively. The asterisk indicates the asymmetric carbon.
The free base form of 5-IT has been described to form skewed 
prisms. The bioxalate salt form has also been documented. 
The forms of 5-IT detected in seizures made from the drug 
market are not known (7). Nuclear magnetic resonance (NMR) 
data from two samples test-purchased from Internet retailers 
selling the substance to consumers were found to be 
consistent with the succinate form. Furthermore, 5-IT contains 
an asymmetric carbon and, as such, two enantiomers are 
possible. Information on the enantiomeric forms present on 
the market is not available. No data are available on the purity 
of 5-IT from the seizures or test purchases.
5-(2-Aminopropyl)indole has predominantly been seized as 
powders and tablets, and in one instance in capsules. One 
seizure related to tablets sold as a ‘legal high’ product labelled 
‘Benzo Fury’ which also displayed an image of the chemical 
structure of 5-APB (5-(2-aminopropyl)benzofuran). It should 
be noted that chemical analysis has found that products 
labelled as ‘Benzo Fury’ may contain different new 
psychoactive substances (see Annex 1). ‘Benzo Fury’ products 
(7)  ‘Detections’ is an all-encompassing term, which may include seizures and/or 
collected and/or biological samples. Seizure means a substance available 
(seized) through law enforcement activities (police, customs, border guards, 
etc.). Collected samples are those that are actively collected by drug 
monitoring systems (such as test purchases) for monitoring and research 
purposes. Biological samples are those from human body fluids (urine, blood, 
etc.) and/or specimens (tissues, hair, etc.).
risk assessment. The meeting took place on 11 April 2013 at 
the EMCDDA in Lisbon. The risk assessment was carried out 
on the basis of information provided to the Scientific 
Committee by the Member States, the EMCDDA, Europol and 
the EMA. A list of the extended Scientific Committee and of 
the participants attending the risk assessment meeting is 
included at the end of this publication.
For the risk assessment, the extended Scientific Committee 
considered the following information resources:
(i)  Technical report on 5-(2-aminopropyl)indole; 
(ii)  Study examining the inhibition of human monoamine 
oxidase (MAO) by the new psychoactive substance 
5-(2-aminopropyl)indole (5-IT) (6);
(iii)  EMCDDA–Europol Joint Report on a new psychoactive 
substance 5-(2-aminopropyl)indole;
(iv)  Scientific articles, official reports, grey literature and 
Internet drug user discussion forums;
(v)  Risk assessment of new psychoactive substances: 
Operating guidelines; and,
(vi)  Council Decision 2005/387/JHA of 10 May 2005 on the 
information exchange, risk assessment and control of 
new psychoactive substances.
I  Physical and chemical description of 5-(2-aminopropyl)indole and its mechanisms of action, including its medical value
5-(2-Aminopropyl)indole is a synthetic derivative of indole 
substituted at the phenyl side of the indole ring system 
(position 5). It is a positional isomer of alpha-
methyltryptamine (AMT), which belongs to the tryptamine 
family, many of which have hallucinogenic and other 
psychoactive effects in humans. 5-(2-Aminopropyl)indole also 
contains the sub-structure of alpha-methylphenethylamine 
and therefore it could be considered to be a ring-substituted 
phenethylamine, many of which are stimulants. In addition, 
5-(2-aminopropyl)indole is structurally similar to the 
aminopropylbenzofurans, specifically 5-APB 
(5-(2-aminopropyl)benzofuran). Despite the structural 
similarities of 5-IT to AMT, 5-APB and phenethylamines such 
as MDA, it is difficult to predict the pharmacological profile of 
5-IT based on a comparison with these other substances due 
to potential differences in mechanisms of action. Limited data 
(6)  EMCDDA-commissioned study undertaken by Instituto de Ciencia y 
Tecnología de Alimentos y Nutrición, ICTAN-CSIC, Spain. See Annex 2.
N
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H2N
CH3
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Molecular formula: C
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H
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N
2
Molecular weight: 174.24 g/mol (base)
Monoisotopic mass: 174.1157 Da
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or suspended) for 5-IT in the European Union or in the 
Member States that responded to the information request by 
the EMA that was launched under Article 5 of the Council 
Decision. There is no information that 5-IT is used for the 
manufacture of a medicinal product or an active 
pharmaceutical ingredient (API) of a medicinal product in the 
European Union. However, it should be noted that there is no 
European Union database on the synthetic routes of all 
registered medicinal products. Therefore, the use of 5-IT 
cannot be ruled out with certainty.
There are no data available from scientific studies on the 
pharmacokinetics of 5-IT. Limited information is available from 
self-reports that may provide an indication of the 
pharmacokinetic parameters such as time of onset of desired 
effects, adverse effects, or duration of action of 5-IT. One user 
report noted that 5-IT has long-lasting stimulant effects of 
about twelve hours when 20 mg is taken orally. Limited, and 
sometimes conflicting, user reports from Internet drug user 
discussion forums mention the time course of effects. In some 
cases, this includes an apparent delayed onset. If this is the 
case, some users may take additional amounts of 5-IT, thus 
increasing the risk of acute toxicity.
In terms of pharmacodynamics, a study commissioned by the 
EMCDDA in 2013 found that racemic 5-IT is a reversible, 
competitive and highly selective inhibitor of monoamine 
oxidase-A (MAO-A) (IC
50
 of 1.6 μM and K
i
 of 0.25 μM) but not 
MAO-B (9). In addition, an in vitro experimental comparison 
found 5-IT to be less potent than the known MAO-A inhibitors 
clorgyline and harmaline, but more potent than toloxatone and 
moclobemide.
A study from 1968 that investigated the inhibition of MAO by 
5-IT and its five isomers reported the IC
50
 values for 5-IT, 
6-(2-aminopropyl)indole (6-IT) and 3-(2-aminopropyl)indole 
(AMT), as 22, 4.6 and 58 μM, respectively. These substances 
were also evaluated for their ability to antagonise 
pentylenetetrazole/reserpine-induced tonic extensor seizures in 
mice. 5-(2-Aminopropyl)indole appeared to be less active than 
6-IT but more active than AMT with regards to anti-reserpine 
activity. AMT has been shown to induce stimulant effects in 
mice; however, 5-IT has yet to be studied in this respect.
No animal studies were identified that investigated the median 
lethal dose (LD
50
) of 5-IT.
No animal studies were identified that investigated the 
potential for self-administration of 5-IT.
No human studies were identified that investigated the 
psychological and/or behavioural effects of 5-IT.
(9)  IC is the inhibitory concentration, Ki is the inhibition constant. 
were originally associated with 5-APB or 6-APB 
(6-(2-aminopropyl)benzofuran). In several of the fatalities an 
empty bag labelled ‘6-APB’ was present at the scene, but 
6-APB was not detected in post-mortem samples. A small 
number of tablets resembling ecstasy (8) have also been 
seized that were found to contain 5-IT.
In some seizures, 5-IT has been reported to be the only 
psychoactive substance detected. There have been a small 
number of seizures where 5-IT has been found in combination 
with: 5,6-methylenedioxy-2-aminoindane (MDAI); 
methylthienylpropamine (1-(thiophen-2-yl)-2-
methylaminopropane, MPA) and caffeine; diphenyl(pyrrolidin-
2-yl)methanol (diphenylprolinol, D2PM); and ethylphenidate. 
No quantitative data were provided.
Analysis using gas chromatography (GC) and liquid 
chromatography (LC) coupled with mass spectrometry (MS) is 
straightforward with suitable equipment and analytical 
reference material. No such material was available when 5-IT 
emerged. Given that the isomer 3-(2-aminopropyl)indole 
(AMT) produces virtually identical mass spectra under some 
conditions, some Member States have reported that they were 
unable to discriminate between these two substances. The EU 
early-warning system has made efforts to highlight this issue 
and provide technical information to Member States to 
facilitate the discrimination between the two. No information 
was provided regarding the possible presence of the other 
isomers on the drug market. The implementation of suitable 
chromatographic techniques would be expected to allow 
successful separation if the reference materials are available 
for comparison. A full analytical profile is provided in Annex 1. 
Infrared spectroscopy can also be useful for bulk analysis of 
pure compounds.
The synthesis of 5-IT was first published in 1963. 
5-(2-Aminopropyl)indole is mentioned in patents that claim 
derivatives of this compound, and a broad range of other 
arylethylamines, as prodrugs that may have potential 
medicinal applications. It should be noted that this does not 
necessarily mean that these will be commercialised. 
5-(2-Aminopropyl)indole is available as an analytical reference 
standard and for use in scientific research. There are no known 
uses of 5-IT as a component in industrial, cosmetic or 
agricultural products. There are currently no other indications 
that 5-IT may be used for other legitimate purposes.
5-(2-Aminopropyl)indole has no established or acknowledged 
medical value or use (human or veterinary) in the European 
Union. There is no marketing authorisation (existing, ongoing 
(8)  The term ecstasy here is used in a broad sense to refer to tablets that contain 
MDMA (or related substances) or are presented as containing such 
substances.
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specific adverse health effects of 5-IT when administered 
through these routes. However, some of these routes, for 
example injection, may have associated health risks.
Systematic data are not routinely collected in Europe on acute 
toxicity related to 5-IT and no studies were identified in the 
literature.
Although there have been reports of detection of 5-IT in 
non-fatal intoxications, there is insufficient clinical details in 
these reports to be able to determine the clinical pattern of 
acute toxicity. In one case where 5-IT was the only substance 
detected, the observed adverse effects were tachycardia, 
mydriasis, agitation and tremor. In the other cases, 5-IT was 
detected along with other substances. In some of these, 
tachycardia, mydriasis, agitation and tremor were again 
reported. In addition, fatigue, hallucinations, unconsciousness, 
hypertension and hyperthermia were also observed. The 
presence of other substances may account, at least in part, for 
some or all of the effects. In addition, details of a non-
analytically confirmed case were provided where the 
symptoms included restlessness, agitation, disorientation, 
shivering, sweating, mydriasis, tachycardia and hyperthermia.
Self-reports of adverse effects (including those on Internet 
discussion forums) include increased heart rate, anorexia, 
diuresis, slight hyperthermia, muscle rigidity and jaw 
clenching. The limitations of self-reports, including the fact 
that users may be unaware of or misinformed about the 
substance they have consumed, should be borne in mind 
when interpreting these reports — users may have taken other 
substances that may account for some or all of the effects 
described.
As some users may be unaware that they have taken 5-IT (for 
example, by consuming a ‘Benzo Fury’ product or a tablet 
containing 5-IT), it is likely that the acute toxicity related to the 
use of the substance is under-reported.
Four Member States have reported a total of 24 fatalities 
where 5-IT has been detected in post-mortem samples: 15 in 
Sweden, four in Hungary, four in the United Kingdom and one 
in Germany. These occurred between April and August 2012. 
The individuals were aged between 19 and 55 years old, with 
only one older than 40 (mean age 31 with a 95 % confidence 
interval of 27 to 34 and an interquartile range between 24 and 
33). Twenty-one were male, one was female and in the 
remaining two cases the sex was not reported. In seven of the 
cases no other substances were detected. In the remaining 
cases, 5-IT was present along with one or more other 
substances. While it is not possible to determine with 
certainty the role of 5-IT in all of these fatalities, in some cases 
it has been specifically noted in the cause of death.
I  Chemical precursors that are used for the manufacture of 5-(2-aminopropyl)indole
There is no information that suggests that 5-IT is 
manufactured in the European Union. One Member State 
reported a seizure of a bulk quantity of 5-IT powder (20.5 kg) 
that had been shipped from, and apparently manufactured in, 
India. The chemical precursors and the synthetic routes used 
to manufacture the 5-IT detected in the European Union are 
unknown. Therefore, the impurities and side-products are also 
unknown.
One classic approach used for the synthesis of 5-IT includes a 
condensation reaction using indole-5-carboxaldehyde and 
nitroethane as starting materials. The resulting intermediate 
can then be reduced to produce 5-IT. Other methods and 
reagents of reduction may also be used. The starting materials 
appear to be commercially available and are not under 
international control. These reactions are feasible in basic 
laboratory settings and do not require sophisticated 
equipment. Further synthetic routes are possible and more 
details are provided in Annex 1.
I  Health risks associated with 5-(2-aminopropyl)indole
I Individual health risks
The assessment of individual health risks includes a 
consideration of the acute and chronic toxicity of 5-IT, as well 
as its dependence potential, and its similarities to and 
differences from other chemically related substances.
Despite the structural similarities of 5-IT to AMT, 5-APB and 
phenethylamines such as MDA, it is difficult to predict the 
pharmacological profile of 5-IT based on a comparison with 
these other substances due to potential differences in 
mechanisms of action.
There is limited information available on the main routes of 
administration for 5-IT. In two non-fatal intoxications the route 
of administration was nasal insufflation (snorting). A small 
number of user reports from Internet drug discussion forums 
suggest that routes of administration include oral ingestion 
(swallowing), nasal insufflation, sublingual, intravenous 
injection and rectal insertion. These routes of administration 
are consistent with the forms of 5-IT encountered in seizures 
and test-purchases. There is no information in relation to the 
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It is important to note that a number of different new 
psychoactive substances have been detected in products sold 
as ‘Benzo Fury’. A non-representative Internet survey 
conducted among readers of a dance music magazine and the 
Guardian newspaper found that overall 2.4 % of respondents 
and 3 % of ‘regular clubbers’ from the United Kingdom 
reported use of ‘Benzo Fury’ in the last year.
One Member State reported the detection of 5-IT in biological 
samples from 10 individuals not related to non-fatal 
intoxications and fatalities. The individuals were suspected to 
have committed minor drug offences or were people in drug 
treatment programmes. Additional information on these cases 
is not available to allow further analysis.
While the routes of administration have been discussed 
above, it is noteworthy that in a small number of cases 
injecting has been reported. Injecting drugs can be associated 
with a range of public health risks, including bacterial 
infections and blood borne viruses such as human 
immunodeficiency virus, hepatitis C and hepatitis B.
It is likely that 5-IT will be used in similar environments as 
other stimulants. This would include the home, bars, 
nightclubs and music festivals.
There is limited information on the route of supply of 5-IT. 
Since June 2012, 5-IT has been seized in seven Member 
States, as well as in Croatia and Norway. It has typically been 
seized as a powder. A small number of tablets, and, in one 
instance, capsules have been seized. Aside from the bulk 
seizure noted below, the powder seizures weighed between 
0.2 and 97.3 grams. In one case, seven tablets were seized 
that resembled ecstasy. Customs authorities in two Member 
States seized small packages containing 5-IT that had been 
posted from other Member States.
Information from the structured Internet search conducted by 
the EMCDDA suggests that 5-IT is commercially marketed 
through Internet shops selling ‘legal highs’ or ‘research 
chemicals’. In some non-fatal intoxications and in one fatality 
it was reported that the users had sourced 5-IT on the 
Internet. The analysis of two test purchases that were sold as 
5-IT from Internet shops confirmed the presence of the 
substance.
The Internet search identified a number of chemical suppliers 
on a trade website that claimed to be able to supply 5-IT in 
bulk quantities. One report was received of a bulk seizure 
(20.5 kg) of 5-IT shipped from India.
While there are insufficient clinical details on the non-fatal and 
fatal intoxications to be able to determine the clinical pattern 
of acute toxicity, evidence of hyperthermia was reported in 
several cases.
Given the limited information available on the pharmacology 
of 5-IT, it is difficult to predict any potential drug interactions 
or contra-indications (including those that may arise from the 
use of alcohol and/or tobacco). However, the MAO inhibition 
activity of 5-IT may result in potential interactions with drugs 
acting on the monoaminergic system.
No experimental studies were identified that investigated the 
potential for chronic 5-IT toxicity in humans, including 
reproductive toxicity, genotoxicity and carcinogenic potential.
There appear to be no published studies on the tolerance or 
dependence producing potential of 5-IT.
I Public health risks
The public health risks associated with 5-IT may be 
categorised in terms of: patterns of use (extent, frequency, 
route of administration, etc.); availability and quality of the 
drug; information, availability and levels of knowledge 
amongst users; and negative health consequences.
In some cases, 5-IT is being sold and consumed as a 
substance in its own right. Similar to other stimulant drugs, 
users may combine 5-IT with other substances (stimulants 
and/or depressants including alcohol). However, some users 
have taken 5-IT unknowingly along with or instead of other 
substances, particularly stimulants.
There is no information on the purity of the 5-IT that is present 
on the drug market. In some of the seizures and test 
purchases, 5-IT has been reported to be the only psychoactive 
substance detected. In addition, there have been a small 
number of seizures where 5-IT has been found in combination 
with other psychoactive substances, particularly stimulants 
(e.g. ethylphenidate, methylthienopropamine).
There are no prevalence data on the use of 5-IT. However, 5-IT 
has been detected in a ‘legal high’ product labelled as ‘Benzo 
Fury’. Furthermore, ‘Benzo Fury’ was reported to have been 
taken in three non-fatal intoxications. It is therefore relevant to 
consider the available data on the use of ‘Benzo Fury’. In 
addition, a small number of tablets that resembled ecstasy 
have also been found to contain 5-IT. Users who take such 
ecstasy tablets may also be exposed to 5-IT.
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I  Information on any assessment of 5-(2-aminopropyl)indole in the United Nations system
The World Health Organization is the specialised agency of the 
United Nations designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the 1961 United Nations Single Convention 
on Narcotic Drugs, and the 1971 United Nations Convention on 
Psychotropic Substances. On 10 October 2012 the World 
Health Organization informed the EMCDDA that 
5-(2-aminopropyl)indole is currently not under assessment and 
has not been under assessment by the United Nations system.
I  Description of the control measures that are applicable to 5-(2-aminopropyl)indole in the Member States
5-(2-Aminopropyl)indole is not listed for control in the 1961 
United Nations Single Convention on Narcotic Drugs or in the 
1971 United Nations Convention on Psychotropic Substances 
(together ‘UN drug conventions’).
Cyprus and Denmark control 5-(2-aminopropyl)indole under 
legislation by virtue of their obligations under the UN drug 
conventions. Twenty-five Member States, Croatia, Turkey and 
Norway do not control 5-(2-aminopropyl)indole by virtue of 
their obligations under the UN drug conventions.
Five countries use other legislative measures to control 
5-(2-aminopropyl)indole. In Austria, 5-(2-aminopropyl)indole is 
subject to control measures according to the law on new 
psychoactive substances. In Hungary, 5-(2-aminopropyl)
indole is controlled as a new psychoactive substance by 
Government Decree 66/2012. In Sweden, 5-(2-aminopropyl)
indole is regulated under the Act on the Prohibition of Certain 
Goods Dangerous to Health. In Germany, 5-(2-aminopropyl)
indole is regulated under the Medical Products Act. In Norway 
5-(2-aminopropyl)indole is regulated under the Medicines Act.
I  Options for control and the possible consequences of the control measures
Under Article 9.1 of the Council Decision, the option for 
control that is available at European Union level is for the 
I  Social risks associated with 5-(2-aminopropyl)indole
There is a lack of information on the social risks associated 
with 5-IT.
One Member State reported the detection of 5-IT in biological 
samples from 10 individuals suspected to have committed 
minor drug offences or people that are in drug treatment 
programmes. Additional information on these cases is not 
available to allow further analysis.
There have been no studies that have investigated the impact 
of 5-IT use on educational outcomes such as attendance, 
concentration and exam performance. Similarly, there is no 
information on the effect of 5-IT use on performance/
attendance at work, career progression, effects on personal 
relationships or neglect of family.
It is not possible at this time to estimate whether 5-IT is 
associated with higher healthcare costs than other stimulant 
drugs.
I
  Information on the level of involvement of 
organised crime and information on 
seizures and/or detections by the 
authorities, and the manufacture of 
5-(2-aminopropyl)indole
There is no information to suggest the involvement of 
organised crime or criminal groups in the manufacture, 
distribution (trafficking) and supply of 5-IT. However, as noted 
above, in one Member State seven tablets were seized that 
resembled ecstasy. Further information about this case would 
be required to assess whether or not there were any links to 
organised crime.
In one Member State where 5-IT is controlled, a case of 
unlawful supply was reported. This involved distribution at 
street level and using the postal system.
See section on health risks and Annex 1 for more details of 
seizures or detections related to 5-IT.
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I Conclusion
5-(2-Aminopropyl)indole appears to be a stimulant substance. 
It is a synthetic derivative of indole substituted at the phenyl 
side of the indole ring system. It is found mostly as a powder 
but also in tablets and capsules. The information that is 
available suggests that the most commonly reported routes of 
administration of 5-IT may be orally and by insufflation. One 
Member State reported that it might also be injected. It has no 
established or acknowledged medical use (human or 
veterinary) in the European Union. There are no indications 
that it may be used for any other purpose aside from as an 
analytical reference standard and in scientific research.
5-(2-Aminopropyl)indole is not listed for control in the 1961 
United Nations Single Convention on Narcotic Drugs or in the 
1971 United Nations Convention on Psychotropic Substances. 
5-(2-Aminopropyl)indole is currently not under assessment 
and has not been under assessment by the United Nations 
system. Two Member States control 5-(2-aminopropyl)indole 
under drug control legislation. Five Member States control 
5-(2-aminopropyl)indole under other legislation.
5-(2-Aminopropyl)indole has emerged on the ‘legal highs’ 
market where it is sold as a ‘research chemical’ and has been 
detected in a ‘legal high’ product labelled ‘Benzo fury’. 5-IT is 
sold on the Internet and in bricks and mortar head shops. In 
addition, it has also been detected in tablets resembling 
ecstasy. In some cases, analysis of samples has found 5-IT to 
be the sole psychoactive substance present. In other cases, it 
has been found in combination with other new psychoactive 
substances, particularly stimulants. There is limited 
information that it is also sold by street-level drug dealers.
5-(2-Aminopropyl)indole has been detected in seven Member 
States, as well as in Croatia and Norway. There are no 
prevalence data on the use of 5-IT. Limited information 
suggests that there may be some interest in using 5-IT among 
certain drug user groups. However, further information on the 
size of the demand and the characteristics of these groups is 
not available. There is no specific information on the social 
risks that may be related to 5-IT.
There is no information to suggest the involvement of 
organised crime in the manufacture, distribution (trafficking) 
and supply. There is no information to suggest that 5-IT is 
manufactured in the European Union. The chemical 
precursors and the synthetic routes used to manufacture the 
5-IT detected in the European Union are unknown. There has 
been one report of a seizure of a bulk quantity of 5-IT powder 
(20.5 kg) that had been shipped from, and apparently 
manufactured in, India. The starting materials used in some of 
the synthetic routes described in the literature are 
commercially available and are not under international control.
Member States to submit the new psychoactive substance 
5-(2-aminopropyl)indole to control measures and criminal 
penalties, as provided for under their legislation, by virtue of 
their obligations under the 1971 United Nations Convention 
on Psychotropic Substances. There are no studies on the 
possible consequences of such control measures on 5-IT. If 
this option of control is pursued, the Committee considers 
that the following consequences are possible. Some of these 
may apply to any new psychoactive substance.
n  This control option could be expected to limit the 
availability of 5-IT and hence the further expansion of the 
current open trade in this substance.
n  A health consequence that may result from this control 
option is the benefit brought about by the presumed 
reduction in availability and use.
n  This control option could facilitate the detection, seizure 
and monitoring of 5-IT related to its unlawful manufacture, 
trafficking and use. In so doing, it could facilitate 
cooperation between the judicial authorities and law 
enforcement agencies across the European Union.
n  This control option would imply additional costs for the 
criminal justice system, including forensic services, law 
enforcement and the courts.
n  This control option could lead to replacement with other 
(established or new) psychoactive substances that may in 
themselves have public health consequences.
n  It is difficult to predict the impact of this control option on 
current or future research by the pharmaceutical or 
chemical industries.
n  This control option could create an illicit market in 5-IT with 
the increased risk of associated criminal activity, including 
organised crime. This could include covert sales of 5-IT on 
the Internet or in bricks and mortar head shops.
n  This control option could impact on both the quality/purity 
and price of any 5-IT still available on the illicit market. The 
extent to which this will impact on public health, criminality 
or levels of use is difficult to predict.
In order to examine the consequences of control, the 
Committee wishes to note that it will be important to monitor 
for the presence of 5-IT on the market post-control, should 
this control option be pursued.
Aside from the option for control under those stipulated in 
Article 9.1 of the Council Decision, other options for control 
may be available to Member States. These may include 
medicines legislation or restricting the importation and supply 
of the substance as some other Member States (and Norway) 
have already done.
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widely available and used, the implications for public health 
could be significant.
Many of the questions posed by the lack of evidence on the 
health and social risks of 5-IT, as for any new psychoactive 
substance, could be answered through further research. Areas 
where additional information would be important include: 
prevalence and patterns of use (including targeted studies 
that examine user groups and risk behaviours); market studies; 
chemical profiling studies; receptor binding and functional 
activity studies; metabolic pathway studies; behavioural 
studies; clinical patterns of acute and chronic toxicity in 
humans; the potential interaction between 5-IT and other 
substances (in particular those that affect the monoaminergic 
system); the dependence and abuse potential; and the social 
risks associated with its use.
The Committee notes that a decision to control 
5-(2-aminopropyl)indole has the potential to bring with it both 
intended and unintended consequences. Potential intended 
consequences include reduced levels of manufacture, 
availability and ultimately use. This may reduce the health and 
social risks and consequences arising from the use of 5-IT. It is 
important to recognise that a potential unintended 
consequence of control may be the manufacture and 
availability of other substances. Finally, control measures 
should not inhibit the gathering and dissemination of accurate 
information on 5-IT to users, practitioners and decision 
makers.
Several Member States reported that forensic and/or 
toxicological laboratories do not currently have validated 
procedures for the confirmation of 5-IT. This is in part due to 
the initial lack of certified reference material and the fact that 
5-IT is not subject to control measures in some Member 
States. This may have led to under-reporting of 5-IT 
detections.
The acute toxicity of 5-IT appears to include symptoms that 
could be regarded as consistent with monoaminergic toxicity 
(including tachycardia and hyperthermia). In addition, there is 
a possibility of interactions with other substances, including 
medicinal products and stimulants, that act on the 
monoaminergic system. There appear to be no published 
studies assessing the acute or chronic toxicity, psychological 
and behavioural effects, nor the dependence potential of 5-IT 
in humans.
5-(2-Aminopropyl)indole either alone or in combination with 
one or more substances has been detected in 24 fatalities in 
four Member States and 20 non-fatal intoxications in three 
Member States. While it is not possible to determine with 
certainty the role of 5-IT in all of the fatalities, in some cases it 
has been specifically noted in the cause of death.
5-(2-Aminopropyl)indole appears to have been available since 
at least November 2011 although the evidence does not 
suggest it has been widely used. The fatalities associated with 
5-IT occurred over a period of five months in 2012. This raises 
the concern that if this substance were to become more 
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Chemical Abstract Service (CAS) Registry Numbers for 
5-(2-aminopropyl)indole are given in Table 1.
Excluding the abstractable proton on the nitrogen atom a total 
number of six positional isomers exist that can carry the 
2-aminopropyl side chain. The synthesis of 5-(2-aminopropyl)
indole (Figure 1) and its isomers was first described by 
Hofmann and Troxler (1963) and Troxler et al. (1968). Another 
isomer is N-methyltryptamine (NMT), which is commonly 
found in nature (Ott, 1996). A more recent example of the 
preparation of 2-(2-aminopropyl)indole (2-IT) was presented 
by Alhambra et al. (2001), who employed a solid-phase 
approach. The synthesis of the 3-(2-aminopropyl)indole 
(AMT) (4) isomer was first published in 1947 (Snyder and Katz, 
1947). 5-(2-Aminopropyl)indole contains an asymmetric 
carbon but data on the availability of its enantiomeric forms 
on the market (including seized, collected and biological 
samples referred to in this report) are currently not available.
(4)  Abbreviations and code names for AMT found in the literature include: 
α-methyltryptamine, AMT, α-MT, 3-IT, IT-290, IT-403, U-14, 162-E, Ro 3-0926, 
NSC 97069, and Indopan.
I  Section A. Physical, chemical, pharmaceutical and pharmacological information
I  A1. Physical, chemical, and pharmaceutical information
A1.1. Physical and chemical description
Chemical description and names
5-(2-Aminopropyl)indole is a synthetic derivative of indole 
substituted at the phenyl side of the indole ring system 
(position 5). It is a positional isomer of alpha-
methyltryptamine (AMT), which belongs to the tryptamine 
family, many of which show hallucinogenic and other 
psychoactive effects in humans. 5-(2-Aminopropyl)indole also 
contains the sub-structure of alpha-methylphenethylamine 
and therefore could be considered to be a substituted 
phenethylamine, many of which are stimulants. Limited data 
suggests that 5-(2-aminopropyl)indole has stimulant effects 
and possible hallucinogenic effects.
The systematic (International Union of Pure and Applied 
Chemistry, IUPAC) name of 5-(2-aminopropyl)indole is 
1-(1H-indol-5-yl)propan-2-amine and other names that may be 
encountered include α-methyl-1H-indole-5-ethanamine and 
2-(1H-indol-5-yl)-1-methyl-ethylamine. A common 
abbreviation used for 5-(2-aminopropyl)indole is 5-IT (1). To a 
lesser extent the abbreviation 5-API is also used (2). Both 
these abbreviations are used by Internet retailers (3) 
advertising 5-(2-aminopropyl)indole as well as in Internet drug 
user discussion forums (‘drug discussion forums’). This 
suggests that ‘5-IT’ and ‘5-API’ are used as ‘street names’. The 
(1)  The origin of the abbreviation ‘5-IT’ is not known at this time.
(2)  The origin of the abbreviation ‘5-API’ is thought to be derived from 
5-(2-aminopropyl)indole.
(3)  The term ‘Internet retailers’ is used in this report to describe Internet shops 
that offer new psychoactive substances for sale often advertised as ‘legal 
highs’ and ‘research chemicals’. 
ANNEX 1
Technical report on  
5-(2-aminopropyl)indole
Dr Simon Elliott and Dr Simon Brandt
TABLE 1
Chemical Abstract Service (CAS) Registry Numbers for 
5-(2-aminopropyl)indole
CAS Registry Numbers Variant
3784-30-3 Unspecified amine
96875-04-6 Ethanedioate (1:1)/hydrogen oxalate/
bioxalate
1336260-35-5 (R)-Enantiomer amine
1336564-72-7 (S)-Enantiomer amine
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be expected to yield very similar mass spectra. However, the 
implementation of suitable chromatographic techniques 
would be expected to allow successful separation if the 
reference materials are available for comparison.
Consistent with mass spectral behaviour reported for isomeric 
psychoactive tryptamines (Martins et al., 2010), key fragments 
observed under EI-MS conditions (m/z) were: 44 (base peak), 
131, 130, 77, 103, 117. The M•+ (m/z 174) may be detectable at 
a minor relative abundance but may also be absent. CI-MS 
(MeOH as liquid CI reagent) gave the [M+H]+ at m/z 175 as the 
base peak and a prominent fragment at m/z 158 following the 
loss of NH
3
. Positive electrospray tandem mass spectra 
(ESI-MS/MS) yielded m/z values of 77, 103, 117, 130, 143, 
158 (relative abundance values dependent on collision 
energy) with some in-source fragmentation of the protonated 
molecule at m/z 175. When evaluating the ability to 
differentiate between 5-IT and AMT under ESI-MS/MS 
conditions, distinct differences in the relative abundances 
were observed, allowing for the potential use of ion ratios for 
multiple reaction monitoring (MRM) transitions. Thus, for AMT: 
m/z 175/158 (100 % abundance), m/z 175/143 (78 %), m/z 
175/130 (30 %) and for 5-IT: m/z 175/158 (100 % 
abundance), m/z 175/143 (22 %), m/z 175/130 (84 %) (Elliott 
et al., 2012). 
The Regulation on Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH) registered substances 
database hosted by the European Chemicals Agency (ECHA) 
was searched using the CAS Registry Numbers listed above 
and no information was found.
The lack of a rapid qualitative screening method is a limiting 
factor for the detection of 5-(2-aminopropyl)indole in 
biological samples. Furthermore, many European forensic/
toxicological laboratories may not have procedures in place 
for analysing 5-(2-aminopropyl)indole in biological samples. In 
some cases this may be due to the lack of reference standards 
for the drug or difficulties in distinguishing between 
5-(2-aminopropyl)indole and the related compound AMT.
Physical description
The free base form of 5-(2-aminopropyl)indole has been 
described to form skewed prisms (Troxler et al., 1968) and the 
bioxalate salt form has also been documented (Hofmann and 
Troxler, 1963). It has been reported that some Internet 
retailers have advertised 5-(2-aminopropyl)indole as the 
succinate salt. NMR data produced as part of the analysis of 
two collected samples of 5-(2-aminopropyl)indole (reported 
by the United Kingdom) were found to be consistent with the 
succinate form (see data above). The structured Internet 
search conducted by the EMCDDA for the Joint Report also 
noted that 5-(2-aminopropyl)indole hydrochloride was being 
offered for sale (EMCDDA & Europol, 2013a). Analytical 
FIGURE 1
The numbered molecular structure, formula, weight and 
monoisotopic mass of 5-(2-aminopropyl)indole (5). Asterisk 
indicates chiral centre
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Identification and analytical profile
The free base gives a slightly violet response (Keller test) 
whereas the van Urk test results in the formation of a red 
colour (Hofmann and Troxler, 1963). Further information on 
the presumptive tests for 5-(2-aminopropyl)indole are not 
available. The reported melting points are: 81–83 °C (free 
base) (petroleum ether/benzene) (Hofmann and Troxler, 1963 
and Troxler et al., 1968); 199–201 °C (bioxalate salt) 
(methanol/diethyl ether) (Hofmann and Troxler, 1963); 194 °C 
(dec.) (hemisuccinate) (LGC GmbH, 2012). Analysis by high 
performance liquid chromatography diode array detection 
gave λ
max
 values at 218.3 nm and 272.8 nm (Elliott et al., 
2012).
Nuclear magnetic resonance spectroscopy (NMR) data of 
5-(2-aminopropyl)indole succinate (6): 1H NMR (300 MHz, 
CD
3
OD): δ 7.42 (1H, br d, J = 1.1 Hz, H-4), 7.37 (1H, d, J = 8.3 
Hz, H-7), 7.23 (1H, d, J = 3.2 Hz, H-3), 6.98 (1H, dd, J = 8.3 Hz, 
J =1.7 Hz, H-6), 6.41 (1H, dd, J = 3.2 Hz, J = 0.8 Hz, H-2), 
3.57-3.45 (1H, m (consistent with predicted dqd), α-CH), 3.02 
(1H, dd, J
gem
 = 13.8 Hz, 3J = 6.5 Hz, CH
A
H
B
), 2.86 (1H, dd, J
gem
 = 
13.8 Hz, 3J = 8.0 Hz, CH
A
H
B
), 2.51 (4H, s, succinate), 1.26 (3H, 
d, 3J = 6.6 Hz, CH
3
). 13C NMR (75 MHz, CD
3
OD): δ 179.4 
(succinate), 137.0 (C-7a), 129.9 (C-3a), 127.5 (C-5), 126.3 
(C-3), 123.5 (C-6), 121.8 (C-4), 112.6 (C-7), 102.2 (C-2), 50.8 
(α-CH), 42.2 (CH
2
), 32.9 (CH
2
, succinate), 18.5 (CH
3
) (Elliott et 
al., 2012).
Mass spectrometry data: 5-(2-aminopropyl)indole (5-IT) and 
3-(2-aminopropyl)indole (AMT) have been found to produce 
virtually identical mass spectra, especially when applying 
conventional electron ionization mass spectrometry (EI-MS) 
procedures. Thus, all six potential 2-aminopropyl isomers may 
(5)  For additional predicted data, see www.chemspider.com/Chemical-
Structure.25991467.html
(6)  NMR data is provided for 5-(2-aminopropyl)indole succinate as this is the 
form that was encountered in a collected sample that was analysed.
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powder in Sweden. No quantitative data were provided for any 
seized or collected sample reported to the EMCDDA nor 
Europol.
A1.2. Physical/pharmaceutical form
Reports of seizures and collected samples have noted that 
5-(2-aminopropyl)indole has been detected in: brown, pale/
light brown or beige powders; beige tablets bearing markings 
resembling the Lexus logo; brown glittery tablets; blue/green 
unmarked tablets; blue unmarked tablets commercially 
packaged as ‘BENZO FURY’; capsules; and in residues on a 
spoon and in the liquid recovered from a syringe. See section 
C for further details of the seized and collected samples of 
5-(2-aminopropyl)indole.
A1.3. Route of administration and dosage
As noted, 5-(2-aminopropyl)indole has been encountered as 
powders as well as tablets and capsules. These physical forms 
suggest that common routes of administration may be oral 
and by insufflation. Limited information from reports of 
non-fatal intoxications and deaths, and drug discussion 
forums, appear to support this (see below). The succinate salt 
of 5-(2-aminopropyl)indole, confirmed in the two collected 
samples reported by the United Kingdom, may be suitable for 
injection. Significantly, in this respect, Hungary has reported 
that 5-(2-aminopropyl)indole has been found in residues on a 
spoon and in the liquid recovered from a syringe. The 
assessment of the national focal point is that 
5-(2-aminopropyl)indole is being injected in some cases.
In two non-fatal intoxications the route of administration was 
reported as nasal insufflation. A user report from Shulgin and 
Shulgin (1997) noted an example of oral administration of 
20 mg. Drug discussion forums suggest that routes of 
administration include: oral ingestion (swallowing, such as 
‘bombing’ (10)), nasal insufflation (snorting), sublingual, 
intravenous injection and rectal insertion (11). Reported doses 
used include: ’20 mg’ [route of administration not specified], 
’80 mg orally’, ‘bombed 100 mg’, ‘150 mg swallowed’, 
‘insufflated 65 mg’ (12).
(10)  ‘Bombing’ is where a drug is wrapped in cigarette paper (or similar) prior to 
swallowing.
(11)  www.drugs-forum.com/forum/showpost.php?p=1126167&postcount=9 
(12)  www.drugs-forum.com/forum/showthread.php?t=140331  
www.drugs-forum.com/forum/showthread.php?t=172223  
www.bluelight.ru/vb/threads/616728-The-Big-amp-Dandy-5-IT-5-API-
Thread
reference standards are commercially available (7). See 
section A1.2 for a description of the physical forms that have 
been reported.
Methods and chemical precursors used for the manufacture of 
5-(2-aminopropyl)indole
There is currently no information regarding manufacturing 
sites, the chemical precursors or the synthetic routes used for 
the 5-(2-aminopropyl)indole that has been detected on the 
drug market.
One classic approach used for the synthesis of 
5-(2-aminopropyl)indole includes a condensation reaction 
using indole-5-carboxaldehyde and nitroethane. These 
substances are commercially available and are not under 
international control. The resulting 5-(2-methyl-2-nitrovinyl)
indole can then be reduced with lithium aluminium hydride 
(LiAlH
4
) (Hofmann and Troxler, 1963; Troxler et al., 1968). 
Other methods and reagents of reduction, for example those 
also employed during phenylalkylamine synthesis, may equally 
be useful (Guy et al., 2008). The reactions are feasible in an 
amateur laboratory setting and do not require sophisticated 
equipment. In analogy to the reductive amination procedure 
used to obtain a range of phenylalkylamines, the use of 
1-(1H-indol-5-yl)propan-2-one as a potential starting material 
might also be conceivable. However, an example of this 
manufacturing procedure is not available in the literature.
Typical impurities encountered in seized samples
There is currently no information available with regards to 
route-specific by-products produced during the synthesis of 
5-(2-aminopropyl)indole. In addition, no data is currently 
available on the impurities detected in seized and collected 
samples.
In some samples, 5-(2-aminopropyl)indole has been reported 
to be the only psychoactive substance detected. Additionally, 
although not impurities, there have been a small number of 
reports where 5-(2-aminopropyl)indole has been found in 
combination with other psychoactive substances. These 
include: 5,6-methylenedioxy-2-aminoindane (MDAI) in 
Germany; methylthienylpropamine (1-(thiophen-2-yl)-2-
methylaminopropane MPA) and caffeine in tablets bearing 
markings resembling the Lexus logo (8) in Hungary; 
diphenyl(pyrrolidin-2-yl)methanol (diphenylprolinol, D2PM) in 
capsules in Guernsey (9); and ethylphenidate in a beige 
(7)  For example www.logical-standards.com/index.php?mact=Products,cntnt01, 
details,0&cntnt01productid=1811&cntnt01returnid=57; and www.
caymanchem.com/app/template/Product.vm/
catalog/12042;jsessionid=4E0344937486009FBED6743CFB66E902
(8)  It is common to find markings on tablets sold as ‘ecstasy’ including those of 
popular cultural and iconic brands often having an association with quality. 
Lexus is a luxury Japanese car manufacturer.
(9)  British Crown Dependency of the Bailiwick of Guernsey, report received from 
the United Kingdom national focal point.
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TABLE 2
Inhibition values determined from recombinant human 
monoamine oxidase-A assay. Racemic 5-(2-aminopropyl)
indole was used in the form of the hemisuccinate salt
Compound IC
50
 (µM) K
i
 (µM)
K
i
 (µM) 
from IC
50
Clorgyline 0.016 — 0.016
Harmaline 0.020 — 0.004
5-(2-Aminopropyl)indole 1.6 0.25 0.32
Toloxatone 6.7 — 1.3
Moclobemide >500 — —
Shulgin and Shulgin (1997) reported long-lasting stimulant 
properties of around 12 hours duration following oral 
administration of 20 mg. Currently, no data are available on 
the presence and/or properties of single enantiomers. 
Increased potency was found to reside with the (S)-(+)-
enantiomer of AMT in both animals and humans (Nichols, 
1986). Whether a similar relationship exists with 
5-(2-aminopropyl)indole remains to be investigated.
There appears to be no published data on the biotransformation 
(metabolism) of 5-(2-aminopropyl)indole in animals or humans. 
Since this particular isomer carries the side chain at the 
5-position, it is currently unknown whether similar 
transformations occur that have been observed with AMT. Early 
work carried out with in vitro (in rat liver microsomes) and in vivo 
samples (male albino rat urine following intraperitoneal injection 
of 5 mg/kg AMT and incubation with bacterial β-glucuronidase) 
indicated the presence of 6-hydroxy-AMT, 1-(1H-indol-3-yl)
propan-2-one and 1-(6-hydroxy-1H-indol-3-yl)propan-2-one, 
respectively (Szara, 1961). A more recent example of metabolic 
studies in rats was provided by Kanamori et al. (2008) who 
observed the formation of 3-(2-aminopropyl)indolin-2-one, 
2-amino-1-(1H-indol-3-yl)propan-1-ol, 6-hydroxy-AMT and 
7-hydroxy-AMT in urine following enzymatic hydrolysis. In this 
study, four male Wistar rats received an oral dose of 10 mg/kg 
of AMT with urine collected and pooled over a 24 hour period. 
Overall, AMT was found to be poorly metabolised, as indicated 
by the relative contribution of signal intensities under GC-MS 
conditions.
Interactions with other drugs and medicines
Given the limited information that is available on the 
pharmacology of 5-(2-aminopropyl)indole it is difficult to 
predict with accuracy any particular potential drug 
interactions or contraindications. However, as stated above, 
the ability of 5-(2-aminopropyl)indole to inhibit MAO-A in vitro 
may result in potential interactions with drugs acting on the 
monoaminergic system. In particular this may be the case for 
serotonergic drugs that may present a risk of inducing 
serotonin syndrome, the symptoms of which can include 
tachycardia, hyperthermia, muscle rigidity and convulsions 
I  A2. Pharmacology, including pharmacodynamics and pharmacokinetics 
Pharmacodynamics
While detailed pharmacological investigations on 
5-(2-aminopropyl)indole do not appear to have been 
published (13), one study was identified that investigated the 
ability of 5-(2-aminopropyl)indole and its five isomers to inhibit 
monoamine oxidase (MAO). The assay method was based on 
the ability of guinea pig liver homogenate to absorb oxygen 
generated from serotonin as the substrate. The activity was 
expressed as percentage inhibition. The IC
50
 values for 
5-(2-aminopropyl)indole, 6-(2-aminopropyl)indole (6-IT) and 
3-(2-aminopropyl)indole (AMT), for example, were 22, 4.6 and 
58 μM, respectively. These data indicate that 6-IT was the 
most potent inhibitor amongst those three substances. These 
substances were also evaluated for their ability to antagonise 
pentylenetetrazole/reserpine-induced tonic extensor seizures 
in mice. 5-(2-Aminopropyl)indole appeared to be less active 
than 6-IT but more active than AMT with regards to anti-
reserpine activity (Cerletti et al., 1968). While the AMT isomer 
has been shown to induce stimulant effects in mice (including 
body tremor, heightened locomotor activity, mydriasis and 
hyperthermia) (Lessin et al., 1965), the extent to which this 
extends to the remaining isomers, including 5-(2-aminopropyl)
indole, remains to be studied. A short report on the 
6-(2-aminopropyl)indole isomer provided some indication that 
intravenous administration (0.5 mg/kg) resulted in 
hypertension and related sympathomimetic features in dogs 
(Maxwell, 1964).
Given the lack of information on the pharmacological and 
toxicological properties of 5-(2-aminopropyl)indole, and 
drawing on the study by Cerletti et al. (1968) summarised 
above, the EMCDDA commissioned a study designed to 
provide further data on the possible effects of 
5-(2-aminopropyl)indole on monoamine oxidase inhibition 
(Annex 2). This study used an in vitro assay with recombinant 
human MAO-A and B isoenzymes (using kynuramine as 
substrate) based on the procedure published by Herraiz and 
Caparro (2006). The study found that racemic 
5-(2-aminopropyl)indole (in the form of the hemisuccinate 
salt) is a reversible, competitive and highly selective inhibitor 
of MAO-A (IC
50
 of 1.6 μM and K
i
 of 0.25 μM) but not MAO-B. In 
addition, an in vitro experimental comparison found 
5-(2-aminopropyl)indole to be less potent than the known 
MAO-A inhibitors clorgyline and harmaline, but more potent 
than toloxatone and moclobemide (Table 2).
(13)  A literature search on 5-(2-aminopropyl)indole revealed a translated article 
(USSR, Academy of Sciences) on serotonergic properties of several 
tryptamines. However, inspection of the English translation did not appear to 
provide any data on 5-(2-aminopropyl)indole (Buznikov et al., 1965).
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There is no information that 5-(2-aminopropyl)indole is 
currently used in the manufacture of a medicinal product in 
the European Union. However, in the absence of a European 
Union database on the synthetic routes of all medicinal 
products this information cannot be verified. There is no 
marketing authorisation (existing, ongoing or suspended) for 
5-(2-aminopropyl)indole neither in the European Union nor in 
the Member States that responded to the request for 
information from the European Medicines Agency (EMCDDA 
& Europol, 2013a).
I  Section B. Dependence and abuse potential
I B1. Animal in vivo and in vitro data 
No published experimental animal studies were identified that 
examined the dependence and abuse potential of 
5-(2-aminopropyl)indole.
As detailed in section A.2, 5-(2-aminopropyl)indole has been 
shown to act as a relatively potent, selective and reversible 
inhibitor of monoamine oxidase inhibitor-A (MAO-A) in vitro. 
This suggests that it might either by itself or in combination 
with other substances potentiate serotonergic effects. 
Although 5-(2-aminopropyl)indole did not inhibit human 
recombinant MAO-B in vitro up to 500 μM (Annex 2), the 
possibility of increased levels of other monoamines such as 
dopamine and noradrenaline may not be fully excluded. 
However, further studies are needed to investigate the 
dependence or abuse potential of this substance.
I B2. Human data
There are no published cases in the scientific or grey literature 
nor user reports describing the potential for dependence or 
abuse potential for 5-(2-aminopropyl)indole. Additionally, 
there have been no studies investigating the dependence 
and/or abuse potential of 5-(2-aminopropyl)indole in humans. 
Information from local, regional or national drug treatment 
agencies about the dependence and abuse potential of 
5-(2-aminopropyl)indole is not available. As noted, Shulgin 
and Shulgin (1997) provided some limited information that 
5-(2-aminopropyl)indole may show long-lasting stimulant 
properties in humans for about twelve hours when 20 mg is 
given orally.
(Boyer & Shannon, 2005). In the context of 5-(2-aminopropyl)
indole use, there may be a potential risk from the 
(concomitant) use of medicinal products (e.g. selective 
serotonin reuptake inhibitors (SSRIs)) as well as stimulant 
drugs that act on the monoaminergic system. These include 
amphetamine, MDMA (and other phenethylamines) and 
cathinone derivatives (e.g. mephedrone, 
4-methylethcathinone). In this respect, some of these drugs 
have been detected in the biological samples from the 
non-fatal intoxications and deaths detailed in section D. It may 
be the case that a possible synergistic interaction may have 
played a role in these cases.
Pharmacokinetics
No animal studies were identified that investigated the 
pharmacokinetics of 5-(2-aminopropyl)indole. There is limited 
information available from Internet reports or from drug 
discussion forums that could be used to determine 
pharmacokinetic parameters such as time of onset of desired 
effects, adverse effects, or duration of action of 
5-(2-aminopropyl)indole. As noted, Shulgin and Shulgin 
(1997) provided some limited information noting that 
5-(2-aminopropyl)indole has long-lasting stimulant effects in 
humans of about twelve hours when 20 mg is given orally.
I A3. Psychological and behavioural effects
No studies were identified that investigated the psychological 
and/or behavioural effects of 5-(2-aminopropyl)indole. As 
mentioned above, Shulgin and Shulgin (1997) provided some 
limited information noting that 5-(2-aminopropyl)indole may 
show long-lasting stimulant properties in humans for about 
twelve hours when 20 mg is given orally. The physical effects 
reported were increased heart rate, anorexia, diuresis, and 
slight hyperthermia. No further relevant details were reported. 
Section D1.2.1 discusses some of the effects that have been 
self-reported by users on drug discussion forums.
I A4. Legitimate uses of the product 
5-(2-Aminopropyl)indole is available as an analytical reference 
standard and is used in scientific research. 5-(2-Aminopropyl)
indole is mentioned in patents that claim derivatives of this 
compound and a broad range of other arylethylamines as 
pro-drugs which may have potential medicinal applications 
(Jenkins & Sturmer, 2012; Van Wijngaarden et al., 1988). 
There are currently no other indications that 5-(2-aminopropyl)
indole may be used for other legitimate purposes. There are no 
known uses of 5-(2-aminopropyl)indole as a component in 
industrial, cosmetic or agricultural products.
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of residues found on a spoon and one report where 
5-(2-aminopropyl)indole was recovered from the liquid in a 
syringe (Hungary). This may suggest that 5-(2-aminopropyl)
indole is being injected by some users. See Appendix for 
details of seizures and collected samples reported to 
EMCDDA and Europol.
Two collected samples from the United Kingdom that were 
purchased from Internet retailers were found to be consistent 
with the succinate form of 5-(2-aminopropyl)indole.
Sweden reported the detection of 5-(2-aminopropyl)indole in 
10 biological samples (one blood; nine urine) from individuals 
suspected to have committed minor drug offences or people 
that are in drug treatment programmes. Further information 
on these cases is not available.
Availability from Internet retailers
A structured Internet search was conducted in March 2013 
using the EMCDDA snapshot methodology to identify Internet 
retailers offering 5-(2-aminopropyl)indole for sale (16). Five 
Internet retailers were identified that currently offered the 
substance for sale to consumers in the European Union. In 
addition two further sites were identified that stated that 
5-(2-aminopropyl)indole would be available for sale soon. On 
two of the sites offering the drug for sale all of the 
5-(2-aminopropyl)indole products were out of stock and on 
one of these sites the prices given were promotional prices. 
Between them, the five retailers offered a total of 21 products 
for sale that claimed to contain 5-(2-aminopropyl)indole (11 
products in powder form, two in capsules and eight for which 
the physical form was not stated). Three sites quoted prices in 
GBP, one in EUR and one did not state the price. Three sites 
offered 5-(2-aminopropyl)indole in powder form. The price per 
gram ranged from GBP 32 to 40. The largest quantity offered 
for sale was 5 grams at GBP 22.95 per gram. One site offered 
5-(2-aminopropyl)indole in capsule form although no prices 
‘Fury’) as containing 6-APB or 5-APB, a structured search of the European 
database on new drugs (EDND) found that seized and collected samples of 
‘Benzo Fury’ products have contained: 6-APB; 5-APB; D2PM; pentylone with 
caffeine, lidocaine and procaine; AM-2201 (tentative identification); and 
5-(2-aminopropyl)indole. Additionally, published studies involving the 
analysis of collected and biological samples suggest that ‘Benzo Fury’ 
products contain: 6-APB; 5-APB; D2PM; and 1-benzylpiperazine (BZP) with 
3-trifluoromethylphenylpiperazine (3-TFMPP) and caffeine (Ayres & Bond, 
2012; Baron et al., 2011; Wood et al., 2011; Wood et al. 2012).
(16)  The Internet search engine ‘google.co.uk’ was searched (March 2013) for 
Internet retailers offering 5-(2-aminopropyl)indole for sale. On the advanced 
search page, Google was configured so that results were not narrowed by 
language and region. The search string used was: buy ‘5-IT’ OR ‘5-API’ OR 
‘5-(2-aminopropyl)indole’. The first 100 sites were reviewed in full then 
sampling continued until 20 successive sites unrelated to the sale of 
5-(2-aminopropyl)indole were identified. Websites that offered 
5-(2-aminopropyl)indole for sale were reviewed and relevant information, 
such as the amount offered (mass of powder, number of capsules/pellets) 
and cost of purchase was recorded on a structured reporting form.
I Section C. Prevalence of use
Information from seizures, collected and biological 
samples
The first official notification of 5-(2-aminopropyl)indole to the 
EU early-warning system was 1 June 2012 by the Norwegian 
national focal point. The reporting form details the seizure of 
one zip-lock bag containing 1 gram of light brown powder 
intercepted at Oslo Airport, Gardermoen, on 17 April 2012 by 
customs authorities. The identification was based on the 
analytical technique of GC-MS alone.
Seven Member States (Denmark, Germany, Finland, Hungary, 
the Netherlands, Sweden and the United Kingdom) and 
Norway have reported seizures of 5-(2-aminopropyl)indole.
At the time of writing the Joint Report, several Member States 
reported that many forensic and/or toxicological laboratories 
did not have validated procedures for the confirmation of 
5-(2-aminopropyl)indole in seized, collected and biological 
samples (EMCDDA and Europol, 2013a). The lack of certified 
reference material has meant that some laboratories could not 
distinguish 5-(2-aminopropyl)indole from the related 
compound AMT which was also present in samples seized on 
the drug market at the time. Furthermore, in the case of 
biological samples there is no rapid qualitative screening 
method for the detection of 5-(2-aminopropyl)indole. Overall, 
this may have led to the under-reporting of 5-(2-aminopropyl)
indole.
5-(2-Aminopropyl)indole has typically been encountered in 
seizures and collected samples in the form of powders, as well 
as in tablets and capsules. Where information has been 
provided, the quantities of powder ranged from 0.2 grams 
(Hungary) to 20.5 kilograms (the Netherlands). Hungary 
reported a seizure of seven beige tablets bearing markings 
resembling the Lexus logo (14). This may suggest that 
5-(2-aminopropyl)indole is being sold as ‘ecstasy’, as Europol 
have reported that tablets containing MDMA and bearing this 
logo, as well as a tablet punch (for imprinting logos on tablets 
as part of the manufacturing process), have been seized in the 
past. In Sweden, blue/green unmarked tablets and brown 
glittery tablets were also seized. In the United Kingdom, blue 
unmarked tablets were seized from a head shop and were 
found in commercial packages marked ‘Benzo Fury’ that also 
displayed an image of the chemical structure of 5-APB 
(5-(2-aminopropyl)benzofuran) (15). There has been one report 
(14)  It is common to find markings on tablets sold as ‘ecstasy’ including those of 
popular cultural and iconic brands often having an association with quality. 
Lexus is a Japanese car manufacturer.
(15)  Although Internet retailers typically advertise ‘Benzo Fury’ products (or using 
synonyms such as ‘BENZO FURY’, ‘BenzoFury’, ‘Benzo-fury’, ’Benzo’, and 
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overall, 2.4 % of respondents (n=7,700) and 3 % of ‘regular 
clubbers’ from the United Kingdom reported use of ‘Benzo 
Fury’ in the last year. In comparison, the self-reported last year 
prevalence for ‘regular clubbers’ of mephedrone was 30 %, 
MDAI was 3 % and methylone was 2 % (Mixmag, 2012). The 
second study conducted among self-reported users of new 
psychoactive substance mainly from Ireland (n=329), found 
that of the 159 respondents who reported using ‘party pills’ 
and ‘liquid highs’, 1.3 % (2/159) had used a product named 
‘Benzo Fury’; while none of the respondents reported use of 
6-APB (Kelleher et al., 2011).
Data from the National Poisons Information Service (NPIS) in 
the United Kingdom indicate that there have been a small 
number of telephone calls and Toxbase access requests in 
relation to 6-APB. No information was provided on 
5-(2-aminopropyl)indole itself (Health Protection Agency, 2012). 
5-(2-Aminopropyl)indole in tablets resembling ‘ecstasy’ 
Hungary reported the seizure of seven tablets that contained 
both 5-(2-aminopropyl)indole and methylthienylpropamine 
bearing markings resembling the Lexus logo (Appendix). As 
noted, Europol have reported MDMA tablets and a tablet 
punch (for stamping logos on tablets) bearing the Lexus logo 
have been seized in the past. It may be the case that some 
ecstasy users are at risk of exposure to 5-(2-aminopropyl)
indole. In this respect, drug prevalence estimates suggest that 
about 2 million Europeans (aged 15–64) have used ecstasy 
during the last year (17) (EMCDDA & Europol, 2013b). However, 
as noted, the total number of such types of tablets containing 
5-(2-aminopropyl)indole that have been reported so far is 
small and limited to one country.
I Section D. Health risks
I D1. Acute health effects
D1.1. Animal data
No studies were identified that investigated the acute toxicity 
of 5-(2-aminopropyl)indole in experimental animal models.
(17)  European estimates are computed from national estimates weighted by the 
population of the relevant age group in each country. They are based on 
surveys conducted between 2004 and 2010/11 (mainly 2007–2010) and 
therefore do not refer to a single year. The term ecstasy is used in a broad 
sense to refer to substances that contain MDMA or other substances that are 
presented as ecstasy.
were stated. The quantities of 5-(2-aminopropyl)indole per 
capsule were 80 mg and 100 mg. The site claimed that the 
effects of the 80 mg capsules last 3–4 hours and those of the 
100 mg capsules last 5–6 hours. Some of the websites 
suggested that there is a similarity between 5-(2-aminopropyl)
indole and 5-APB, 6-APB and MPA. No site offered products 
that contained both 5-(2-aminopropyl)indole and other new 
psychoactive substances. In addition, a number of suppliers 
were identified on the trade website tradevv.com that claimed 
to supply 5-(2-aminopropyl)indole in bulk quantities. However, 
details of the amounts offered and prices were only available 
on direct application to these suppliers.
Prevalence of use
No studies were identified that investigated the prevalence of 
5-(2-aminopropyl)indole use.
One Member State reported the detection of 5-(2-aminopropyl)
indole in biological samples from 10 individuals not related to 
non-fatal intoxications and deaths. The individuals were 
suspected to have committed minor drug offences or were 
people in drug treatment programmes. Information on these 
cases is not available to allow further analysis.
In addition, 5-(2-aminopropyl)indole has been detected in a 
‘legal high’ product labelled as ‘Benzo fury’ (see footnote 15). 
Furthermore, in three non-fatal intoxications ‘Benzo Fury’ was 
the product reported to have been taken. In several of the 
fatalities an empty bag labelled 6-APB (6-(2-aminopropyl)
benzofuran) was found, but not detected in post-mortem 
samples. A small number of tablets resembling ecstasy have 
also been found to contain 5-(2-aminopropyl)indole. It is 
therefore relevant to discuss the available prevalence data on 
the use of ‘Benzo Fury’ products, 6-APB and ecstasy.
Information on the use of ‘Benzo fury’ products and 
6-APB
Two Internet surveys were identified that examined the use of 
‘Benzo Fury’. One of these also examined the use of 6-APB. 
While these surveys provide some indication of the use of 
‘Benzofury’ products, the results are not generalisable to other 
groups and populations as they are non-probablistic 
convenience sample surveys. In addition it is important to note 
both that the surveys predate the detection of 
5-(2-aminopropyl)indole on the European drug market and a 
number of different new psychoactive substances have been 
detected in products sold as ‘Benzo Fury’ (see footnote 15).
The first survey was conducted among readers of a dance 
music magazine and the Guardian newspaper. It found that, 
RISK ASSESSMENTS I 5-(2-Aminopropyl)indole (5-IT)
24 / 50
Annex 1
users describe taking other drugs prior to or with 
5-(2-aminopropyl)indole.
Some of the websites suggest that there is a structural 
similarity between 5-(2-aminopropyl)indole and 5-ABP, MPA 
and AMT. In addition one websites alludes to 
5-(2-aminopropyl)indole having similar effects to 5-APB while 
another lists the product as ‘5-IT (similar to 6-APB)’.
Drugs Forum:
The first discussion thread on the Drugs Forum website for 
5-(2-aminopropyl)indole appears to have been started in 
August 2010; while the first user report relating to this 
substance appears to be in November 2011. The thread also 
includes reference to 5-(2-aminopropyl)indole as an isomer of 
AMT, with citation of various online reference sources (e.g. 
Wikipedia) as well as Shulgin and Shulgin’s TiHKAL (1997).
User reports:
One user, after an apparent intravenous injection of 
5-(2-aminopropyl)indole, reported ‘incredible rush, not so 
strong stimulating properties like speed, feeling is more like … 
aMT + weak speed’. Another reported ‘very small psychedelic 
properties, reminds [me] of aMT’. Following 80 mg ‘bombed’ a 
user concluded that ‘I would say this somewhere in effects 
between 6-APB and MDAI with an amphetamine like quality 
but also quite reminiscent of aMT just nowhere near as 
psychedelic and with no nausea or body load’. Another user 
who ‘bombed’ 100 mg of 5-(2-aminopropyl)indole 
summarised ‘no come down, very stable euphoria and clear 
thoughts with a little bit of trippiness’. The use of 6-APB was 
mentioned by a number of users and one indicated a 
comparison stating that 5-(2-aminopropyl)indole was ‘quite 
comparable to 6-APB, but not quite as debilitating in its 
intenseness, not as euphoric, with a slightly shorter duration’.
Bluelight:
Amongst initial user discussions regarding the relative risk of 
taking ‘new research chemicals’ such as 5-(2-aminopropyl)
indole and making predictions of effects, one user who took 
20 mg (unknown route) stated that ‘the duration on 5-IT is 
rather long, with the entire experience lasting about 10 hours, 
probably slightly more’. Similar duration of effect was also 
noted by another user who had taken 100 mg: ‘I still felt it after 
seven hours on a 100 mg dose’. However, another user in 
response to an extended come down experience of 22 hours 
postulated whether the user had actually taken 
5-(2-aminopropyl)indole. Dose discussions also featured and 
one user surmised that ‘at high doses I have seen reports of 
dysphoria, delirium, pain, unconsciousness, confusion, 
hyperthermia, tremors. I experienced only positive effects but 
I would not recommend a higher starting dose for these 
reasons’.
While detailed pharmacological investigations on 
5-(2-aminopropyl)indole do not appear to have been 
published (18), as noted in section A2, one study was identified 
that investigated the ability of 5-(2-aminopropyl)indole and its 
five isomers to inhibit monoamine oxidase (MAO). The assay 
method was based on the ability of guinea pig liver 
homogenate to absorb oxygen generated from serotonin as 
the substrate. The activity was expressed as percentage 
inhibition. The IC
50
 values for 5-(2-aminopropyl)indole, 
6-(2-aminopropyl)indole (6-IT) and 3-(2-aminopropyl)indole 
(AMT), for example, were 22, 4.6 and 58 μM, respectively. 
These data indicate that the 6-IT isomer was the most potent 
inhibitor amongst those three substances. These substances 
were also evaluated for their ability to antagonise 
pentylenetetrazole/reserpine-induced tonic extensor seizures 
in mice. 5-(2-Aminopropyl)indole appeared to be less active 
than 6-IT but more active than the AMT isomer with regards to 
anti-reserpine activity (Cerletti et al., 1968). AMT has been 
shown to induce stimulant effects in mice (including body 
tremor, heightened locomotor activity, mydriasis and 
hyperthermia) (Lessin et al., 1965); the extent to which this 
extends to the remaining isomers, including 5-(2-aminopropyl)
indole, remains to be studied. A short report on the 
6-(2-aminopropyl)indole isomer provided some indication that 
intravenous administration (0.5 mg/kg) resulted in 
hypertension and related sympathomimetic features in dogs 
(Maxwell, 1964).
D1.2. Human data
D1.2.1. User reports
As noted, Shulgin and Shulgin (1997) reported that 
5-(2-aminopropyl)indole may show long-lasting stimulant 
properties in humans of about twelve hours following oral 
administration of 20 mg. Effects reported were increased 
heart-rate, anorexia, diuresis, and slight hyperthermia. No 
further information was provided.
There are some user reports on drug discussion forums that 
discuss the use of 5-(2-aminopropyl)indole (e.g. (19)). These 
need to be interpreted with caution as there was no analytical 
confirmation of the substances used. In addition, some of the 
(18)  As noted in footnote 13, a literature search on 5-(2-aminopropyl)indole 
revealed a translated article (USSR, Academy of Sciences) on serotonergic 
properties of several tryptamines. However, inspection of the English 
translation did not appear to provide any data on 5-(2-aminopropyl)indole 
(Buznikov et al., 1965).
(19)  www.drugs-forum.com/forum/showthread.php?t=140331 
www.drugs-forum.com/forum/showthread.php?t=172223 
www.drugs-forum.com/forum/showpost.php?p=1126167&postcount=9 
www.bluelight.ru/vb/threads/616728-The-Big-amp-Dandy-5-IT-5-API-
Thread
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5-(2-aminopropyl)indole and benzodiazepines were 
detected (20).
Non-fatal cases reported by the United Kingdom
The United Kingdom reported two non-fatal intoxications 
associated with the second death case that is detailed in 
section D1.2.3. The two individuals had also reportedly 
ingested ‘Benzo Fury’ from the same source as the deceased. 
They were also examined at the hospital but neither appeared 
to have suffered any significant toxic effects. No further 
information on drug history or the amounts of ‘Benzo Fury’ 
taken is available.
D1.2.3. 5-(2-Aminopropyl)indole associated deaths
Four Member States (Sweden, the United Kingdom, Hungary 
and Germany) reported a total of 24 deaths associated with 
5-(2-aminopropyl)indole (Table 3).
Deaths reported by Sweden
Sweden reported 15 deaths associated with 
5-(2-aminopropyl)indole. The deaths occurred between April 
2012 and July 2012. In 14 of the cases the cause of death was 
considered to be related to 5-(2-aminopropyl)indole. In the 
remaining case the cause was ‘disease’. In the large majority 
of cases the cause of death was considered to be drug related 
although the ICD10 coding does not include naming 
5-(2-aminopropyl)indole specifically. In the remaining cases, 
the cause was not ICD10 coded as being drug related and 
they were recorded as being due to epilepsy and, in another 
case, sudden cardiac arrest. In 14 cases the 5-(2-aminopropyl)
indole concentration in post-mortem femoral blood ranged 
from between 0.7 and 5.1 μg/g blood. In one case the 
concentration of 5-(2-aminopropyl)indole was 18.6 μg/g 
femoral blood. All of the decedents were male. Thirteen were 
aged between 20 and 30 years, the remaining two were over 
30 years old. In two cases 5-(2-aminopropyl)indole was the 
only substance reported as detected. In the remaining cases 
5-(2-aminopropyl)indole was found in combination with 
‘pharmaceuticals’ or ‘other drugs of abuse’. Notably some of 
these drugs have monoaminergic activity, such as sertraline, 
venlafaxine and MDMA.
(20)  The example provided in the Joint Report of a non-fatal intoxication involving 
an 18-year-old female who had taken one capsule of 5-(2-aminopropyl)
indole of unknown strength actually relates to a self-report that was not 
analytically confirmed. Although in the text of the Joint Report it appears that 
this case was one of the 13 non-fatal intoxications reported by Sweden, 
further information from the national focal point has confirmed that it was 
not part of this case series and instead was documented prior to the 
introduction of biological screening for 5-(2-aminopropyl)indole. See 
EMCDDA–Europol (2013a) for details further details of this case. 
D1.2.2. 5-(2-Aminopropyl)indole associated acute toxicity
Two Member States (Sweden and the United Kingdom) 
reported a total of 20 non-fatal intoxications associated with 
5-(2-aminopropyl)indole.
German police reported to Europol a case where a powder 
was seized from an unconscious person. It is not known if this 
is a non-fatal intoxication associated with 5-(2-aminopropyl)
indole as further details are not available and therefore this 
case has not been included in this report.
Non-fatal cases reported by Sweden
Sweden reported 18 non-fatal intoxications where 
5-(2-aminopropyl)indole was detected in biological samples. 
They occurred between January and August 2012.
Of the 18 cases, 16 were male and two were female. Their 
ages ranged between 17 and 53; the most common age was 
between 20 to 30 years, with 11 of the 18 falling into this 
bracket. In six cases, the individual stated they had taken ‘5-IT’ 
(a commonly used abbreviation for 5-(2-aminopropyl)indole), 
in three cases the stated intake was ‘benzofury’. Other cases 
mentioned taking ethylphenidate, etizolam, MDPV and/or 
6-APB. One person said they had been ‘drinking only coca 
cola from an unknown source’; another person stated they had 
taken ‘an unknown substance’. 5-(2-Aminopropyl)indole was 
analytically confirmed in each case although the 
concentration was not determined. Other drugs detected in 
these cases were: ethylphenidate, 4-,5- or 6-APB, 
4-methylethcathinone, buprenorphine, methylphenidate (and 
metabolites), 4-fluoroamphetamine, oxazepam, temazepam, 
diazepam metabolites, methylthienylpropamine, 
methoxetamine, 4-hydroxymidazolam (midazolam metabolite), 
ketamine, GHB (gamma-hydroxybutyrate), PMMA (para-
methoxymethamphetamine), amphetamine, 
N-methamphetamine, 4-methylamphetamine, α-PVP, 
cannabis, thiopental, pentobarbital, benzoylecgonine (cocaine 
metabolite), ethanol and metabolites. It is not known whether 
any of these substances (e.g. benzodiazepines and 
barbiturates) had been administered as part of medical 
treatment.
The route of administration of 5-(2-aminopropyl)indole was 
indicated in two cases where the individuals reported having 
taken it by nasal insufflation. In three cases the individuals 
reported that they had sourced 5-(2-aminopropyl)indole from 
the Internet. The sources of 5-(2-aminopropyl)indole for the 
remaining 15 cases are not available.
The reported symptoms included dilated pupils, sweating, 
restlessness, fatigue, disorientation, agitation, mydriasis, 
anxiety, tachycardia, hypertension and hyperpyrexia. 
Hallucinations were mentioned in one individual where only 
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The cause of death in the first case involving the 33-year-old 
was ‘fatality following the ingestion of “Benzo Fury”’ and 
certified as ‘5-(2- aminopropyl)indole (5-API; 5-IT) and 
Benzofuran toxicity’. The individual was treated in hospital 
prior to death. Analysis of the blood revealed an approximate 
5-(2-aminopropyl)indole concentration of 0.379 mg/L in 
unpreserved post-mortem blood. Other drugs detected in the 
blood included 5-APB (0.016 mg/L), 6-APB (0.057 mg/L), 
diazepam (0.037 mg/L), nordiazepam (0.009 mg/L), 
temazepam (0.001 mg/L) and AMT (less than 0.01 mg/L). 
Urine analysis detected amphetamine, 5-(2-aminopropyl)
indole, 5-APB, 6-APB, AMT and benzodiazepines. In addition, 
5-(2-aminopropyl)indole, 5-APB, 6-APB, AMT and diazepam 
were detected in the stomach contents.
In the second case involving the 19-year-old, the toxicological 
investigation revealed 5-(2-aminopropyl)indole at a 
concentration of approximately 0.513 mg/L in ante-mortem 
blood (the deceased was admitted to hospital prior to death) 
and approximately 0.30 mg/L in unpreserved post-mortem 
blood. Other drugs detected included MDMA (0.468 mg/L 
ante-mortem blood, 0.502 mg/L post-mortem blood), MDA 
(0.036 mg/L ante-mortem blood, 0.046 mg/L post-mortem 
blood), 6-APB (0.005 mg/L post-mortem blood only), atropine 
and lignocaine. These drugs were also detected in the urine 
and stomach contents. It was noted that there was a high 
concentration of MDMA, which on its own was considered to 
be at a fatal level. However, a cumulative/synergistic effect of 
5-(2-aminopropyl)indole was not excluded and the cause of 
death was recorded as ‘multidrug toxicity’. This case is linked 
to the seizure of 116 blue tablets in branded packets labelled 
as ‘BENZO FURY’ that were found to contain 
5-(2-aminopropyl)indole.
The remaining two deaths were reported in a letter to the 
British Medical Journal. The letter reports that 
5-(2-aminopropyl)indole was detected in the post-mortem 
blood samples of two young adults. The authors note that 
5-(2-aminopropyl)indole was ‘found in combination with other 
drugs in one case’; while in the second case ‘5-APB/6-APB’ 
was detected (Seetohul et al., 2012). It was ascertained from 
the national focal point that these cases were distinct from 
the other two cases reported by the United Kingdom. No 
further details are available at this time.
Death reported by Germany
Germany reported one death associated with 
5-(2-aminopropyl)indole.
The report stated that on 23 May 2012, a 29-year-old man who 
was not known as drug user was found dead in his apartment. 
A powder was found under his bed which was analysed and 
found to contain 5-(2-aminopropyl)indole. The initial urine 
screen indicated a positive result for amphetamine/
Deaths reported by Hungary
Hungary reported four deaths associated with 
5-(2-aminopropyl)indole. Two of these deaths occurred in April 
2012 and were originally believed to be related to AMT, which 
was reported as detected in post-mortem biological samples. 
The decedents, a 40-year-old male and a 35-year-old female, 
were found together in a flat.
The post-mortem concentrations determined as AMT were 
34 mg/L and 84 mg/L respectively. These figures are provided 
only to show them relative to each other. The biological 
samples were no longer available for re-analysis. However, the 
re-analysis of powders found at the scene identified the 
presence of 5-(2-aminopropyl)indole and not AMT. The 
Hungarian national focal point noted that ‘based on the active 
agent identified in the substance found next to the bodies it is 
assumed that the cause of the deaths was 5-(2-aminopropyl)
indole intoxication rather than AMT intoxication’. As already 
noted, analytical reference standards were not available at the 
time and it was difficult to distinguish between 
5-(2-aminopropyl)indole and AMT. No other substances were 
reported as detected.
The pathological cause of death in each case was ‘circulatory 
failure and respiratory failure, where the direct causes of 
death … were the results of 5-IT intoxication’ and in the case 
of the female ‘the respiration of vomited content of stomach 
might have had a limited impact too’. There were signs of 
‘prolonged sexual intercourse, extreme hyperthermia and the 
use of new psychoactive substances’.
The third death occurred in May 2012 and involved a 38-year-
old male known ‘drug abuser’ who was found dead in his 
apartment along with injection paraphernalia. A sachet found 
next to the body contained 5-(2-aminopropyl)indole. ‘The 
toxicological analysis identified 5-IT in the blood’ but no 
quantitative information was available. No other substances 
were reported as detected. The cause of death was attributed 
to drug intoxication and respiratory failure.
The fourth death occurred in June/July 2012; a 24-year-old 
male died having purchased a product called ‘Pink’ from the 
Internet. The substance had been dissolved in water and 
consumed. ‘Toxicological analysis identified 5-IT in the blood 
and stomach’. No other substances were reported as 
detected. The cause of death was attributed to circulatory and 
respiratory failure as a result of drug use and overdose.
Deaths reported by the United Kingdom
The United Kingdom reported four deaths associated with 
5-(2-aminopropyl)indole. Details are only provided for two of 
these cases, both of which occurred in June 2012. The 
decedents were both male; one was 33 years old, the other 
was 19 years old.
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methamphetamine. The preliminary autopsy report provided 
‘neither a hint on external assault and battery nor on a 
pathological-anatomic cause of death’. Further toxicological 
investigations revealed a high concentration of 
5-(2-aminopropyl)indole in the blood and urine samples (the 
blood sample contained >1200 ng/ml) (Schäper et al., 2013). 
No other substances were reported as detected. The final 
cause of death has not yet been recorded; however, the 
German national focal point reported that intoxication by 
5-(2-aminopropyl)indole is plausible.
This case highlights that there may be cross-reactivity issues 
with some screening tests. Further research is required to 
investigate this.
TABLE 3
Summary of deaths associated with 5-(2-aminopropyl)indole (5-IT). For reference against other reported cases µg/g is largely 
comparable to mg/L
Date of death
Deceased
(age/sex)
5-(2-Aminopropyl)
indole toxicological 
findings (blood)
Other drugs detected  
(blood unless otherwise indicated)
ICD10 coding or  
descriptive cause of death
Sweden
April 2012 23-year-old male 18.6 µg/g AM–2201
4-APB (urine)
Toxic effects of non-medicinal substance.
May 2012 31-year-old male 2.3 µg/g 0.05 µg/g hydroxyzine
0.04 µg/g etizolam
Poisoning by hallucinogen.
May 2012 24-year-old male 2.4 µg/g 0.03 µg/g zopiclone
0.003 µg/g ethylphenidate
0.03 µg/g ritalinic acid
Un-attended death. No other cause found.
May 2012 28-year-old male 3.8 µg/g 26 µg levitiracetam Epilepsy.
May 2012 20-year-old male 1.1 µg/g 0.02 µg/g benzoylecgonine
0.002 µg/g THC
pentedrone [no quantitative data 
provided]
Sudden cardiac arrest.
May 2012 31-year-old male 5.1 µg/g 0.04 µg/g 7-amino-clonazepam
0.01 µg/g perphenazine
0.12 µg /g ethylphenidate 2.6 µg/g 
ritalinic acid
0.0002 µg/g methylphenidate 
Poisoning by drugs.
May 2012 33-year-old male 4.2 µg/g Poisoning by hallucinogen.
May 2012 28-year-old male 2.5 µg/g 9.2 µg/g pregabalin Poisoning by drugs.
May 2012 40-year-old male 1.0 µg/g Poisoning by hallucinogen.
June 2012 31-year-old male 1.6 µg/g 0.2 µg/g alimemazine 0.1 µg/g 
desmethylalimemazine
Un-attended death. No other cause found.
June 2012 29-year-old male 0.7 µg/g 0.18 µg/g ethylphenidate
1.9 µg/g ritalinic acid
Accidental poisoning by drugs.
June 2012 55-year-old male 2.1 µg/g 0.9 µg/g carisoprodol
meprobamate (not quantitated)
0.32 µg/g 7-amino-clonazepam
Poisoning by drugs.
June 2012 30-year-old male 2.1 µg/g 0.7 µg/g sertraline
2.5 µg/g desmethylsertraline
1.0 µg/g venlafaxine
0.5 µg/g o-desmethylvenlafaxine
Poisoning by drugs.
June 2012 24-year-old male 1.1 µg/g 0.02 µg /g benzoylecgonine
0.53 µg/g MDMA
0.03 µg/g MDA
Poisoning by hallucinogen.
July 2012 28-year-old male 1.7 µg/g 0.008 µg/g ethylphenidate Un-attended death. No other cause found.
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Date of death
Deceased
(age/sex)
5-(2-Aminopropyl)
indole toxicological 
findings (blood)
Other drugs detected  
(blood unless otherwise indicated)
ICD10 coding or  
descriptive cause of death
Hungary
April 2012 40-year-old male Not available None Circulatory failure and respiratory failure were 
the direct causes of death as a result of 5-IT 
intoxication.
April 2012 35-year-old 
female
Not available None Circulatory failure and respiratory failure were 
the direct causes of death as a result of 5-IT 
intoxication. The respiration of vomited content 
of stomach might had a limited impact too.
May 2012 38-year-old male Not available None Brain oedema, frothy respiratory tract 
secretion, pulmonal oedema and minor 
degeneration of cardiac muscle were observed 
in the body. The report concludes that based 
on the case history and the diagnostic report 
drug intoxication and respiratory failure as a 
consequence of intoxication are the assumed 
causes of death.
June/
July 2012
24-year-old male Not available None The cause of death was circulatory and 
respiratory failure that developed due to 
metabolic failure, severe brain oedema, 
pulmonal oedema and cardiac failure. The 
report concludes that, in all probability, the 
cause of that was drugs use and overdose.
United Kingdom
June 2012 33-year-old male 0.379 mg/L 0.016 mg/L 5-APB
0.057 mg/L 6-APB
0.037 mg/L diazepam
0.009 mg/L nordiazepam
0.001 mg/L temazepam
<0.001 mg/L AMT
The level of 5-IT is an approximate 
determination in unpreserved post mortem 
blood.
All other analytes were detected in post 
mortem blood.
Urine analysis detected amphetamine, 5-IT, 
5-APB, 6-APB, AMT and benzodiazepines.
In addition, 5-IT, 5-APB, 6-APB, AMT and 
diazepam were detected in the stomach 
contents 
June 2012 19-year-old male 0.30 mg/L 0.502 mg/L MDMA
0.046 mg/L MDA
0.005 mg/L 6-APB
Atropine
Lignocaine
The level of 5-IT is an approximate 
determination in unpreserved post mortem 
blood. 0.513 mg/L 5-IT was determined in ante 
mortem blood.
Cause of death noted to be ‘multi-drug toxicity’.
All other analytes were detected in post 
mortem blood.
Prior to 24 
August 2012
‘young adult’ Not available ‘Other drugs’ Reported in letter to the British Medical 
Journal, no further details available.
Prior to 24 
August 2012
‘young adult’ Not available ‘5/6-APB’ Reported in letter to the British Medical 
Journal, no further details available.
Germany
May 2012 29-year-old male >1200 ng/ml None The final cause of death has not yet been 
recorded; however, the national focal point 
reported that intoxication by 5-(2-aminopropyl)
indole is plausible.
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I D2. Chronic health effects
D2.1. Animal data
No studies were identified that investigated the chronic health 
effects of 5-(2-aminopropyl)indole in animals.
D2.2. Human data
No studies were identified that investigated the chronic health 
effects of 5-(2-aminopropyl)indole in humans.
I D3. Factors affecting public health risks
D3.1. Availability and quality of the new psychoactive 
substance on the market 
5-(2-Aminopropyl)indole is offered for sale by Internet retailers 
as a substance in its own right. 5-(2-Aminopropyl)indole has 
also been detected in a ‘legal high’ type product branded as 
‘Benzo Fury’. There has also been one report from Hungary 
where 5-(2-aminopropyl)indole was seized as tablets 
resembling ‘ecstasy’. Some individuals may be exposed to 
5-(2-aminopropyl)indole intentionally. Others may be exposed 
unintentionally and unknowingly after consuming a product 
with no indication that it contains 5-(2-aminopropyl)indole or 
following its ingestion as a component of a mixture of other 
active substances (e.g. MDAI, 5- or 6-APB).
D3.2. Availability of the information, degree of 
knowledge and perceptions amongst users concerning 
the psychoactive substance and its effects
There is relatively limited information on drug discussion 
forums regarding the effects and potential health/adverse 
effects related to the use of 5-(2-aminopropyl)indole. On some 
drug discussion forums the use of 5-(2-aminopropyl)indole as 
a drug in its own right has been discussed. This is supported 
by the finding that two collected samples from Internet 
retailers contained 5-(2-aminopropyl)indole (in powders) as 
well as the fact that Internet retailers offer various dosage 
forms claiming to contain the substance (section C). 
Nevertheless, it is likely that the information, degree of 
knowledge and perceptions amongst users concerning 
5-(2-aminopropyl)indole and its effects are likely to be limited. 
In addition some users may be exposed to 5-(2-aminopropyl)
indole unknowingly given that it has been detected in a ‘legal 
high’ type product labelled as ‘Benzo Fury’ as well as tablets 
resembling ecstasy.
D3.3. Characteristics and behaviour of users 
There are self-reports from users on drug discussion forums 
who believe that they have specifically taken 
5-(2-aminopropyl)indole. In some cases this appears to be in 
order to determine its relative effects compared to related 
compounds such as AMT in particular as well as 5- or 6-APB. 
This suggests a degree of risk-taking behaviour although some 
of the discussions have included harm reduction measures in 
relation to use of ‘new research chemicals’. 
D3.4. Nature and extent of health consequence 
The limited documented information on the acute health 
effects of 5-(2-aminopropyl)indole have been discussed in 
section D1.2. There is insufficient information in the reported 
non-fatal intoxications and deaths where 5-(2-aminopropyl)
indole has been detected to discuss in detail the 
circumstances of these cases. However, from the information 
available, it does not appear that any of these were related to 
road traffic accidents. The information available indicates that 
the presence of 5-(2-aminopropyl)indole has been analytically 
confirmed in a number of acute emergencies associated with 
the substance.
D3.5. Long-term consequences of use
As noted in sections D2.1 and D2.2 no animal or human data 
on the chronic health effects of 5-(2-aminopropyl)indole were 
identified. In particular, there have been no long-term follow 
up studies to determine whether 5-(2-aminopropyl)indole 
users are at greater risk of health deterioration later in life, or 
of developing chronic or life-threatening medical conditions.
D3.6. Conditions under which the new psychoactive 
substance is obtained and used, including context-
related effects and risks
As noted, it appears that the sourcing and use of 
5-(2-aminopropyl)indole is generally related to individuals 
attempting to source the drug itself or when it has been 
inadvertently taken along with or instead of other stimulants. 
As noted in section C, the structured Internet search 
conducted by the EMCDDA identified five English-language 
Internet retailers that offered 5-(2-aminopropyl)indole for sale 
to consumers in the European Union. In addition, in one case 
5-(2-aminopropyl)indole was detected in a ‘legal high’ type 
product labelled as ‘Benzo Fury’ that was sold in a bricks and 
mortar head shop. It is likely that 5-(2-aminopropyl)indole is 
used in the same environments as other stimulants. This 
would be typically, but not restricted to, home environments, 
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bars/pubs, discotheques/nightclubs and outdoor music 
festivals. Limited information from drug discussion forums 
suggest that 5-(2-aminopropyl)indole is used at home and in 
nightclubs.
I Section E. Social risks
I E1. Individual social risks
There is currently no data to be able to determine the impact 
of 5-(2-aminopropyl)indole in this area.
I E2. Possible effects on direct social environment
There is currently no data to be able to determine the impact 
of 5-(2-aminopropyl)indole in this area.
I E3. Possible effects on society as a whole
Sweden reported the detection of 5-(2-aminopropyl)indole in 
10 biological samples (one blood; nine urine) from individuals 
suspected to have committed minor drug offences or people 
that are in drug treatment programmes. Further information 
on these cases is not available to allow further comment.
I E4. Economic costs
Given the lack of data available on acute health emergencies 
and healthcare utilisation related to the use of 
5-(2-aminopropyl)indole, it is not possible at this time to 
estimate whether the substance is associated with greater 
healthcare costs than other stimulant drugs.
I  E5. Possible effects related to the cultural context, for example marginalisation
There is currently no data to be able to determine the impact 
of 5-(2-aminopropyl)indole in this area.
I  E6. Possible appeal of the new psychoactive substance to specific population groups within the general population
There is currently no data to be able to determine the possible 
appeal of 5-(2-aminopropyl)indole to specific population 
groups within the general population.
I Section F. Involvement of organised crime
I  F1. Evidence that criminal groups are systematically involved in production, trafficking and distribution for financial gain
No information has been received by Europol of evidence that 
criminal groups are systematically involved in production, 
trafficking and distribution of 5-(2-aminopropyl)indole for 
financial gain.
I  F2. Impact on the production, trafficking and distribution of other substances, including existing psychoactive substances as well as new psychoactive substances
Based on the information available to ECMDDA and Europol it 
does not appear that the production, trafficking and 
distribution of 5-(2-aminopropyl)indole impact on other 
existing psychoactive substances or new psychoactive 
substances.
I  F3. Evidence of the same groups of people being involved in different types of crime
No information has been received by Europol of evidence of 
the same groups of people being involved in different types of 
crime in connection with 5-(2-aminopropyl)indole.
I  F4. Impact of violence from criminal groups on society as a whole or on social groups or local communities (public order and safety)
No information has been received by Europol on incidents of 
violence in connection with 5-(2-aminopropyl)indole.
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I  F5. Evidence of money laundering practices, or impact of organised crime on other socioeconomic factors in society
No information has been received by Europol on incidents of 
money laundering or the impact of organised crime on other 
socioeconomic factors in society in connection with 
5-(2-aminopropyl)indole.
I  F6. Economic costs and consequences (evasion of taxes or duties, costs to the judicial system) 
There is currently no data to be able to determine the impact 
of 5-(2-aminopropyl)indole in this area.
I F7. Use of violence between or within criminal groups
No information has been received by Europol on incidents of 
violence in connection with 5-(2-aminopropyl)indole.
I  F8. Evidence of strategies to prevent prosecution, for example through corruption or intimidation
No information has been received by Europol on strategies to 
prevent prosecution in connection with 5-(2-aminopropyl)
indole.
RISK ASSESSMENTS I 5-(2-Aminopropyl)indole (5-IT)
32 / 50
Annex 1
References
I  Alhambra, C., Castro, J., Chiara, J. L., Fernández, E., Fernández-Mayoralas, A., Fiandor, J. M., García-
Ochoa, S. and Martín-Ortega, M. D. (2001), ‘An improved two-resin method for the cleavage of 
tertiary amines from REM resin’, Tetrahedron Letters 42(38), pp. 6675–6678.
I  Ayres, T. C. and Bond, J. W. (2012), ‘A chemical analysis examining the pharmacology of novel 
psychoactive substances freely available over the internet and their impact on public (ill)health: legal 
highs or illegal highs?’, BMJ Open 2(4). doi:10.1136/bmjopen-2012-000977.
I  Baron, M., Elie, M. and Elie, L. (2011), ‘An analysis of legal highs: do they contain what it says on the 
tin?’, Drug Testing and Analysis 3(9), pp. 576–581.
I  Boyer, E. W. and Shannon, M. (2005), ‘The serotonin syndrome’, New England Journal of Medicine 
352(11), pp. 1112–1120.
I  Buznikov, G. A., Zherebchenko, P. G. and Chudakova, I. V. (1965), ‘Effect of various indolyl alkyl amines 
on the motor cells of mollusk embryos and the vessels of the rabbit ear’, Byulleten Eksperimental’noi 
Biologii i Meditsiny 59(5), pp. 59–63.
I  Cerletti, A., Taeschler, M. and Weidmann, H. (1968), ‘Pharmacologic studies on the structure–activity 
relationship of hydroxyindole alkylamines’, Advances in Pharmacology (New York) 6(Pt. B), pp. 
233–246.
I  Elliott, S. P., Brandt, S. D., Freeman, S. and Archer, R. P. (2012), ‘AMT (3-(2-aminopropyl)indole) and 
5-IT (5-(2-aminopropyl)indole): an analytical challenge and implications for forensic analysis’, Drug 
Testing and Analysis 5(3) pp. 196–202.
I  EMCDDA and Europol (2013a), EMCDDA–Europol Joint Report on a new psychoactive substance: 
5-(2-aminopropyl)indole, Joint Reports, Publications Office of the European Union, Luxembourg.
I  EMCDDA and Europol (2013b), EU drug markets report: a strategic analysis, Publications Office of 
the European Union, Luxembourg.
I  Guy, M., Freeman, S., Alder, J. F. and Brandt, S. D. (2008), ‘The Henry reaction: spectroscopic studies 
of nitrile and hydroxylamine by-products formed during synthesis of psychoactive phenylalkylamines’, 
Central European Journal of Chemistry 6(4), pp. 526–534.
I  Herraiz, T. and Chaparro, C. (2006), ‘Analysis of monoamine oxidase enzymatic activity by reversed-
phase high performance liquid chromatography and inhibition by beta-carboline alkaloids occurring 
in foods and plants’, Journal of Chromatography A 1120(1–2), pp. 237–243.
I  Hofmann, A. and Troxler, F. (1963), ‘Nouveaux dérivés de l’indole et leur préparation’, patent, 
FR1344579, issued 21.10.1963 to Sandoz S.A. 
I  Jenkins, T. E. and Sturmer, A. G. (2012), ‘Compositions for reducing risks of adverse events caused by 
drug-drug interactions’, patent, WO2012/122412, issued 13.09.2012 to Signature Therapeutics, Inc.
I  Kanamori, T., Kuwayama, K., Tsujikawa, K., Miyaguchi, H., Iwata, Y. T. and Inoue, H. (2008), ‘In vivo 
metabolism of α-methyltryptamine in rats: identification of urinary metabolites’, Xenobiotica 38(12), 
pp. 1476–1486.
I  Kelleher, C., Christie, R., Lalow, K., Fox, J., Bowden, M. and O’Donnell, C. (2011), An overview of new 
psychoactive substances and the outlets supplying them, National Advisory Committee on Drugs, 
Dublin. 
I  Lessin, A. W., Long, R. F. and Parkes, M. W. (1965), ‘Central stimulant actions of α-alkyl substituted 
tryptamines in mice’, British Journal of Pharmacology and Chemotherapy 24(1), 49–67.
I  LGC GmbH, (2012), ‘Certificate of analysis for 5-(2-aminopropyl)indole hemisuccinate’, release date: 
15.10.2012. Available from: http://www.logical-standards.com/uploads/pdfs/english/CERT-
LGCFOR1389.04-19501.pdf
RISK ASSESSMENTS I 5-(2-Aminopropyl)indole (5-IT)
33 / 50
Annex 1
I  Martins, C. P. B., Freeman, S., Alder, J. F., Passie, T. and Brandt, S. D. (2010), ‘The profiling of 
psychoactive tryptamine drug synthesis focusing on mass spectrometry’, Trends in Analytical 
Chemistry 29(4), pp. 285–296.
I  Maxwell, G. M. (1964), ‘The effects of an indole derivative 6-(2’-aminopropyl indole) on the general 
and coronary haemodynamics of the intact dog’, Experientia 20(9), pp. 526–527.
I  Mixmag (2012), ‘The Mixmag/Guardian drug survey’, Mixmag, April, p. 28.
I  National Poisons Information Service and Health Protection Agency (2012), National Poisons 
Information Service Annual Report 2011/2012, Health Protection Agency, London.
I  Nichols, D. E. (1986), ‘Studies of the relationship between molecular structure and hallucinogenic 
activity’, Pharmacology Biochemistry and Behavior 24(2), pp. 335–e40.
I  Ott, J. (1996), Pharmacotheon: entheogenic drugs, their plant sources and history, Natural Products 
Co., Kennewick, Washington.
I  Schäper, J., Fehn, S. and Westphal F. (2013), ‘Designer-drug 5-IT: a fatal case’, Toxichem Krimtech 
80(2), p. 112.
I  Seetohul L.N. et al., (2012) ‘Deaths associated with new designer drug 5-IT’, BMJ 2012;345:e5625 
doi: 10.1136/bmj.e5625
I  Shulgin, A. T. and Shulgin, A. (1997), TiHKAL: the continuation, Transform Press, Berkeley, California, 
pp. 565–569.
I  Snyder, H. R. and Katz, L. (1947), ‘Alkylation of aliphatic nitro compounds with gramine: new synthesis 
of derivatives of tryptamine’, Journal of the American Chemical Society 69(12), pp 3140–3142.
I  Szara, S. (1961), ‘6-Hydroxylation: an important metabolic route for α-methyltryptamine’, Experientia 
17, pp. 76–77. 
I  Troxler, F., Harnisch, A., Bormann, G., Seemann, F. and Szabo, L. (1968), ‘Synthesen von Indolen mit 
(2-Aminoäthyl)-, (2-Aminopropyl)-oder Alkanolamin-Seitenketten am Sechsring. 5. Mitt. über 
synthetische Indol-Verbindungen’, Helvetica Chimica Acta 51(7), pp. 1616–1628. 
I  Van Wijngaarden, I., Den Hartog, J. A. J., Tulp, M. T. M. and Lobbezoo, M. W. (1988), ‘Tertiary arylethyl 
amine derivatives having opiate-antagonistic activity’, patent, EP0289070 A1, issued 02.11.1988 to 
Duphar International Research B.V.
I  Wood, D. M., Davies, S., Puchnarewicz, M., Johnston, A. and Dargan, P. I. (2011), ‘Acute toxicity 
associated with the recreational use of the ketamine derivative methoxetamine’, European Journal of 
Clinical Pharmacology 68(5), pp. 853–856.
I  Wood, D. M., Puchnarewicz, M., Johnston, A. and Dargan, P. I. (2012), ‘A case series of individuals with 
analytically confirmed acute diphenyl-2-pyrrolidinemethanol (D2PM) toxicity’, European Journal of 
Clinical Pharmacology 68(4), pp. 349–353.
RISK ASSESSMENTS I 5-(2-Aminopropyl)indole (5-IT)
34 / 50
Annex 1
I Appendix
Details of seizures and collected samples of 5-(2-aminopropyl)indole (5-IT) reported to the EMCDDA and Europol
Date of seizure  
or collection
Amount and 
physical form
Seizing or 
collecting 
authority
Place of 
seizure or 
collection
Notes Images
Denmark
19/07/2012 One seizure of 
5.1 g light brown 
powder 
Customs Haderslev Powder was found in a small transparent 
bag and with a sticker: ‘5 g 5-IT, Research 
Chemical, Not for human consumption’. 
The bag was inside a ‘standard’ brown 
envelope, and without any sender. The 
post came from United Kingdom. 
Identification based on GC-MS, UPLC-
TOF, H-NMR.
Finland
01/04/2012 One seizure of 
1.1 g of a light 
brown powder
Customs Helsinki Seized in incoming mail. Identification 
based on NMR.
Germany
02/05/2012 1.35 g and a 
further 0.22 g 
together with 
traces of MDAI 
(together with 
other new 
psychoactive 
substances)
Police Hannover The accused stated that he has bought 
the substances via the internet from an 
online shop in the United Kingdom.
12/11/2012 Brown glittery 
tablets (amount 
unknown at 
present)
Police Bavaria ‘Further fragmentary information on 5 
additional cases of detection of 5-IT in 
sezizures [sic] of 1–10 tablets per case 
was reported by the Bavarian Police and 
one case of 1 gram 5-IT.’
Hungary (21)
04/2012 2.4 g of a beige 
powder
Police Tapolca Confirmed as 5-(2-aminopropyl)indole
04/2012 Residues on 
paper, liquid in 
syringe (0.75 ml)
Police Debrecen Confirmed as 5-(2-aminopropyl)indole
04/2012 2.2 g of a brown 
powder
Police Szombathely Confirmed as 5-(2-aminopropyl)indole
05/2012 Residues on 
spoon 
Police Szentes Confirmed as 5-(2-aminopropyl)indole
05/2012 10.2 g of a brown 
powder
Police Tata Confirmed as 5-(2-aminopropyl)indole
(21) The Forensic Institute of the National Tax and Customs Administration of Hungary reported no seizures of 5-(2-aminopropyl)indole.
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Date of seizure  
or collection
Amount and 
physical form
Seizing or 
collecting 
authority
Place of 
seizure or 
collection
Notes Images
06/2012 0.2 g of a 
light-brown 
powder
Police Szigetvár Confirmed as 5-(2-aminopropyl)indole
06/2012 7 beige tablets 
with ‘Lexus’ logo, 
also containing, 
methylthienyl-
propamine and 
caffeine
Police Kiskőrös Confirmed as 5-(2-aminopropyl)indole. 
Weight of tablets: 0.285 g, diameter: 
8.10 mm, thickness: 5.8 mm. The 
identification was carried out by TLC and 
GC/MS based on the laboratory’s ‘own’ 
reference materials (their structure was 
confirmed by NMR).
07/2012 0.2 g of brown 
powder
Police Esztergom Confirmed as 5-(2-aminopropyl)indole
08/2012 97.3 g of a brown 
powder, residues 
on digital scale
Police Szigetvár In this case the investigation confirmed 
the fact of dealing both new psychoactive 
substances (according to schedule ‘C’ 
Gov. Decree 66/2012) and illicit drugs 
(covered by the illicit drugs definition of 
the Penal Code). Mail delivery and selling 
from the flat was also confirmed. The 
business covered the whole country and 
did not concentrate on the area of 
Szigetvár.
09/2012 4.1 g of light 
brown powder
Police Eger Confirmed as 5-(2-aminopropyl)indole
10/2012 0.3 g of light 
brown powder
Police Debrecen Confirmed as 5-(2-aminopropyl)indole
12/2012 0.1 g of brown 
powder
Police Szekszárd Confirmed as 5-(2-aminopropyl)indole
Netherlands
Not available 20.5 kg Customs Not available
Sweden
33 seizures 
incorporating 
36.33 g powder 
and 54 tablets.
Police The first seizure comprising 13 g beige 
powder was seized by the police 
16/05/2012 in Örnsköldsvik city with 
identification based on GC-MS, GC-IRD 
and NMR. 
Examples of seized tablets: one type of 
tablet in 6 materials. These are blue, green 
melange; round and curved with border; 
diameter 9.0 mm, width 4.0 mm, weight 
0.25 g. Another type of tablet that 
occurred only in one material: brown, 
glittery tablet; round and flat and scored; 
diameter 6.0 mm, width 2.9 mm, weight 
0.10 g.
Four seizures in 
total, comprising: 
three seizures of 
a brown powder 
weight a total of 
11.07 g. One 
seizure of five 
tablets
Customs Arlanda 
Airport, 
Sweden
The three packages containing powder 
were from Spain. The package containing 
tablets were sent from United Kingdom.
United Kingdom
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Date of seizure  
or collection
Amount and 
physical form
Seizing or 
collecting 
authority
Place of 
seizure or 
collection
Notes Images
04/2012 500 mg brown 
powder
State’s 
Analyst 
Guernsey
Purchased 
from the 
Internet
Confirmed as 5-(2-aminopropyl)indole 
succinate by NMR.
05/2012 Pale brown 
powder 
TicTac Ltd Purchased 
from Internet
GBP 22.50 
for 500 mg
Product label stated ‘5-IT’ ‘500mg’ ‘NOT 
FOR HUMAN CONSUMPTION’.
Analysis by GCMS. Molecular formula 
confirmed by High Res MS. Confirmed as 
5-(2-aminopropyl)indole succinate by 
proton NMR.
09/06/2012 One seizure of 
116 packets. Blue 
unmarked tablet 
in packet
Police Edinburgh, 
Scotland
During the police investigation of one of 
the fatal cases from the United Kingdom 
where the presence of 5-(2-aminopropyl)
indole was confirmed, the police were 
informed that the product consumed by 
the deceased had been purchased at a 
‘head shop’ in Edinburgh. Police executed 
a search warrant at the Edinburgh 
premises and recovered a large quantity 
of items (160 productions) including bulk 
quantities of powders, herbal material and 
packaged products.
One of the items submitted to the 
Forensic Science Laboratory contained 
116 yellow packages labelled ‘BENZO 
FURY’ with a graphic displaying the 
structure of 5-APB. Four of these 
packages, selected at random, were 
examined and each found to contain a 
single blue unmarked biconvex tablet 
which were each analysed and found to 
contain 5-(2-aminopropyl)indole. Other 
items of interest recovered from the ‘head 
shop’ were: yellow capsules labelled 
‘benzofury’ found to contain brown 
powder containing 5/6-APB; 31 g of brown 
powder found to contain 5/6-APB; 174 
packages (98 of one type and 76 of a 
second type) each containing 1 g of 
crystalline substance identified as 
methylthienylpropamine (MPA).
08/09/2012 One seizure of 
seven red and 
white gelatine 
capsules with no 
markings on them. 
Also contained 
diphenyl prolinol 
(D2PM)
Customs Guernsey The Guernsey Border Agency seized the 
capsules along with a number of Class B 
substances from a person arriving on the 
Island. Analysis was carried out by the 
Guernsey States Analyst.
Norway
17/04/2012 One seizure of 1 g 
in a small bag 
with zip-lock 
Customs Gardermoen, 
Oslo Airport
Identified with MS only.
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I Introduction
Following an examination of the available information on 
5-(2-aminopropyl)indole (5-IT) (1), on 3 October 2012 the 
EMCDDA and Europol launched a Joint Report on the 
substance. It was presented to the Council of the European 
Union, the European Commission and the European 
Medicines Agency on 12 December 2012 (2, 3). 
Consequently, a Technical report will be prepared as a matter 
of priority within a tight deadline in order to be available for the 
risk assessment as requested by the Council of the European 
Union. As identified in the Joint Report, there is a lack of 
information on the pharmacology and toxicology of 
5-(2-aminopropyl)indole. However, a single study published in 
the 1960s indicated that the substance may act as an 
inhibitor of monoamine oxidase (Cerletti et al., 1968). In some 
of the non-fatal intoxications and deaths associated with 
5-(2-aminopropyl)indole that have been reported, symptoms 
typical of monoaminergic toxicity have been noted. These 
include hyperthermia along with dilated pupils, sweating, 
increased heart rate, high blood pressure, agitation, 
restlessness, disorientation and anxiety. The purpose of the 
contract therefore is to conduct in vitro studies on 
5-(2-aminopropyl)indole to investigate its effects on 
monoamine oxidase in order to inform the risk assessment.
(1)  For the purpose of this report the abbreviation ‘5-IT’ is used interchangeably 
with ‘5-(2-aminopropyl)indole’.
(2) OJ L 127, 20.5.2005, p. 32.
(3)  EMCDDA and Europol (2012), EMCDDA–Europol Joint Report on a new 
psychoactive substance: 5-(2-aminopropyl)indole, Publications Office of the 
European Union, Luxembourg.
I Objectives of the study
Experimental work was conducted to determine and evaluate 
the effect of 5-(2-aminopropyl)indole (5-IT) on the human 
monoamine oxidase (MAO) enzyme. In vitro assays 
included the use of recombinant MAO enzymes and 
kynuramine as substrate. Following incubation, the assays 
were analysed using previously validated methods based on 
the analysis of the reaction products by HPLC coupled to 
Diode Array Detector (DAD) and fluorescence detection. The 
two isoenzymes MAO-A and -B were considered. The 
inhibition parameters, IC
50
 (concentration of inhibitor that 
produce 50 % inhibition) and K
i
 (dissociation constant of 
enzyme and inhibitor), were determined using different 
concentrations of substrate and inhibitor and appropriate 
equations. Inhibition of MAO-A by known inhibitors was also 
evaluated and the inhibition parameters (IC
50
) determined. In 
addition, experimental work was undertaken on the mode of 
binding of 5-IT, its mechanism of inhibition and selectivity.
I Experimental
Recombinant human monoamine oxidase-A and B were 
obtained from Gentest BD biosciences (Woburn, MA, USA). 
Kynuramine dihydrobromide, 4-hydroxyquinoline, harmaline, 
clorgyline, R-deprenyl, toloxatone (5-(hydroxymethyl)-3-(3-
methylphenyl)-2-oxazolidinone), and moclobemide (4-chloro-
N-[2-(4-morpholinyl)ethyl]benzamide) were purchased from 
Sigma-Aldrich. 5-IT hemisuccinate (5-API hemisuccinate; 
5-(2-aminopropyl)indole hemisuccinate) was purchased from 
LGC standards. All test compounds were dissolved in milli-q 
ultrapure water and diluted appropriately in 100 mM 
phosphate buffer pH 7.4.
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protein) in 100 mM phosphate buffer (pH 7.4) was incubated 
at 37 ºC for 30 min with or without (control) 5-IT (100 μM), 
and then centrifuged (15000 x g, 15 min) to pellet the protein, 
that was washed with 100 mM phosphate buffer and the 
procedure repeated three times. Finally, the enzyme was 
re-suspended in phosphate buffer and used to measure MAO 
activity, as above. Assays were carried out at least in 
duplicate.
I Chromatographic analysis by RP-HPLC 
The analysis of the kynuramine deamination product 
4-hydroxyquinoline was accomplished by RP-HPLC-DAD and 
fluorescence detection using an HPLC 1050 (Hewlett 
Packard) provided with a 1100 DAD (Agilent) and a 
1046A-fluorescence detector (Hewlett Packard). A 150 mm x 
3.9 mm, 4 μm, Nova-pak C18 column (Waters, Milford, MA, 
USA) was used for separation. Chromatographic conditions 
were: 50 mM ammonium phosphate buffer (pH 3) (buffer A) 
and 20 % of A in acetonitrile (buffer B). Gradient programmed 
from 0 % (100 % A) to 32 % B in 8 min and then 90 % B at 10 
min. The flow rate was 1 ml/min, the column temperature was 
40 ºC and the injection volume was 20 μl.
I Results
I A) In vitro inhibition of human MAO-A by 5-IT
Enzymatic reactions were carried out at different 
concentrations of substrate and the results of the enzyme 
activity against the concentration of substrate fitted to 
nonlinear regression analysis to plot Michaelis-Menten curves 
(Figure 1). The reaction velocity v (μM/min) was obtained from 
the deamination of kynuramine by MAO-A to form 
4-hydroxyquinoline. In that way, calculated values of V
max
 of 
0.8 ± 0.02 μM/min and K
m
 of 61.88 ± 4.6 μM were obtained for 
MAO-A and kynuramine. Subsequently, inhibition of human 
MAO-A by the substance 5-(2-aminopropyl)indole (5-IT) was 
studied in presence of kynuramine as the substrate (250 μM). 
The profile is shown in Figure 2, and it clearly suggests that 
5-IT is an in vitro inhibitor of the human MAO-A with an IC
50
 
value of 1.6 ± 0.1 μM.
I Monoamine oxidase assays (MAO-A and B)
The enzymatic activity of human MAO isozymes was studied 
using protein fractions containing this enzyme by using 
kynuramine as a non-selective substrate (Herraiz and 
Chaparro, 2006). The reaction velocity v (μM/min) was 
obtained from oxidative deamination of kynuramine to form 
under the conditions of the assay 4-hydroxyquinoline that was 
analysed by HPLC-DAD and its concentration calculated from 
a calibration curve of peak area (λ at 320 nm) against 
concentration (Herraiz and Caparro, 2006). To carry out the 
assay, protein fractions containing MAO-A or B were diluted to 
the desired concentrations in 100 mM potassium phosphate 
buffer (pH 7.4). A 0.2 ml reaction mixture containing 0.01–
0.02 mg/ml protein and 0.25 mM kynuramine in 75 mM 
potassium phosphate (pH 7.4) was incubated at 37 ºC for 40 
min. After incubation the reaction was stopped by the addition 
of 2N NaOH (75 μl), followed by the addition of 70 % 
perchloric acid (25 μl), and the sample centrifuged (10000 x 
g) for 6 min. An aliquot of the supernatant (20 μl) was injected 
into the HPLC and the deamination products of kynuramine 
formed during the enzymatic reaction determined by RP-
HPLC-DAD and fluorescence detection. 
I  MAO-A and -B inhibition studies with 5-IT and other inhibitors
MAO-A or -B enzymes were incubated as above with 
kynuramine as a substrate and added with increasing 
concentrations of 5-IT or other inhibitors of MAO-A and B at 
the desired concentration in phosphate buffer (pH 7.4), and 
incubated at 37 ºC for 40 min, as above. IC
50
 values 
(concentration of inhibitor producing 50 % inhibition of 
enzymatic activity) were calculated by fitting (% inhibition vs. 
concentration of inhibitor) to non-linear regression curves or 
by linear regression of inhibition (%) against the log of 
substrate concentration. Assays were carried out at least in 
duplicate.
Kinetic constant of Michaelis-Menten (K
m
) and the maximum 
velocity (V
max
) were obtained from nonlinear regression 
analysis (velocity vs. concentration) using different 
concentrations of substrate. The mechanism of MAO inhibition 
by 5-IT was assessed experimentally by obtaining the 
corresponding double reciprocal Lineweaver-Burk plots of the 
enzyme activity at different concentrations of substrate and 
inhibitor. The secondary plot of the slope from the double 
reciprocal curves versus the concentration of inhibitor was 
used to calculate K
i
 (inhibition constant) values. Kinetic assays 
were carried out at least in duplicate.
To determine the type of binding of 5-IT to MAO-A (i.e. 
reversible or irreversible inhibition), MAO-A (0.025 mg/ml 
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FIGURE 3
Activity of human MAO-B in presence of 5-IT
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FIGURE 4
Inhibition of human MAO-B by (R)-deprenyl
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I  C) Kinetic study of human MAO-A inhibition and determination of Ki (inhibition constant) values
As 5-IT was an inhibitor of human MAO-A, kinetic assays 
corresponding to the activity of this enzyme in the presence of 
increasing concentrations of 5-IT (0–2 μM) were 
accomplished by using various concentration of substrate. The 
corresponding double reciprocal curves (i.e. Lineweaver-Burk 
plots) were obtained experimentally and are given in Figure 5, 
showing that 5-IT is a competitive inhibitor of MAO-A. Thus, in 
the presence of increasing concentrations of 5-IT, the enzyme 
had similar V
max
 (velocity in high concentrations of substrate) 
whereas K
m
 increased with the concentration of inhibitor. The 
inhibition constant K
i
 (dissociation constant of the enzyme-
inhibitor complex) was calculated from a secondary plot of the 
slopes of curves in Figure 5 against the concentration of 
FIGURE 1
Michaelis-Menten curve of kynuramine deamination to form 
4-hydroxyquinole by MAO-A (0.01 mg/ml MAO-A protein and 
kynuramine in 0.2 ml phosphate buffer. 37 ºC, 40 min)
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FIGURE 2
Inhibition of human MAO-A in presence of 5-IT
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I B) In vitro inhibition of human MAO-B by 5-IT
Inhibition of human MAO-B by the substance 5-IT was studied 
in the presence of kynuramine as substrate (250 μM). The 
profile obtained is shown in Figure 3 and clearly shows that 
5-IT was devoid of activity as an inhibitor of recombinant 
human MAO-B. Indeed, in the range used (0–500 μM, 5-IT) no 
inhibition of MAO-B was detected. Instead, under the same 
conditions, R-deprenyl, a selective inhibitor of MAO-B, highly 
inhibited this enzyme at sub-micromolar concentrations 
(Figure 4). As a result of these data, no further studies were 
carried out with MAO-B isoenzyme and 5-IT.
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FIGURE 7
Human MAO-A (0.025 mg/ml, protein conc.) was incubated 
in duplicate with 0 or 100 µM 5-IT at 37 ºC, 30 min. The 5-IT 
removed through successive washing and centrifugation and 
then enzymatic assay was conducted
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I D) Type of binding (reversibility) of 5-IT with MAO-A 
Following incubation of the enzyme MAO-A with 5-IT, and 
after washing to completely remove the 5-IT, the activity of the 
enzyme was fully recovered when compared with a control 
incubated in absence of 5-IT. Therefore, 5-IT binds to MAO-A 
under a reversible type of binding (Figure 7).
I  E) Inhibition of MAO-A by substances used as reference and established inhibitors
Experimental data of the substance 5-IT as an inhibitor of 
MAO-A were compared with data obtained from other known 
inhibitors. For that, several substances including established 
inhibitors of MAO-A were studied under the experimental 
conditions used here. Clorgyline, a well-known irreversible 
inhibitor of MAO-A, demonstrated strong inhibition of human 
MAO-A with an IC
50
 under the experimental conditions used of 
16 ± 2.6 nM (Figure 8). Similarly, the β-carboline harmaline, 
that is a reversible and potent inhibitor of MAO-A provided an 
IC
50
 of 20 nM (Figure 9). 
inhibitor giving a value of K
i
 of 0.25 μM (Figure 6) (intercept on 
the x-axis). 
On the other hand, as the inhibition of 5-IT over MAO-A is 
competitive and the inhibitor is reversible (see below), the 
equation of Cheng-Prusoff (i.e. IC
50
 = K
i
 (1 + S/K
m
) could be 
used to determine K
i
 from the IC
50
 and K
m
 values (Cheng and 
Prusoff, 1973). The K
i
 obtained was 0.32 μM which is in good 
agreement with the one calculated experimentally from the 
double reciprocal curves and secondary plot (Figures 5 and 6).
FIGURE 5
Lineweaver-Burk plot of the MAO-A enzymatic reaction in 
presence of increased concentrations of 5-IT and kynuramine 
used as substrate. Control without 5-IT (■); 0.5 µM 5-IT (▲); 
1 µM 5-IT (▼); 2 µM 5-IT (♦)
25
20
15
10
5
-5
1
/v
 (
µM
-1
 m
in
)
0.01-0.01 0.02 0.03 0.04
1/S (µM-1)
FIGURE 6
Secondary plot of slope of the curves of Lineweaver-Burk plot 
against the concentration of 5-IT as an inhibitor that was 
used to calculate K
i
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FIGURE 8
Inhibition of MAO-A by clorgyline 
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FIGURE 9
Inhibition of MAO-A by harmaline
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Toloxatone (Humoryl), an antidepressant launched in 1984 for 
the treatment of depression and which acts as a 
selective reversible inhibitor of MAO-A (Berlin et al., 1990) 
gave an IC
50 
of 6.71 ± 0.42 μM (Figure 10). Finally, 
moclobemide, another antidepressant that is authorised as a 
medicinal product in some countries and also a selective 
reversible MAO-A inhibitor, gave a poor inhibition of MAO-A in 
vitro with a IC
50
 value higher than 500 μM in our assay system 
(Figure 11). Results obtained with moclobemide suggest that 
it may be a poor inhibitor of MAO-A in vitro although a good 
inhibitor of MAO-A in vivo, probably resulting from a metabolite 
of the substance (Kettler et al., 1990; Fritze et al., 1989). 
FIGURE 10
Inhibition of MAO-A by toloxatone
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FIGURE 11
Inhibition of MAO-A by moclobemide 
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According to the Cheng-Prusoff equation, the K
i
 obtained for 
the mentioned compounds were 0.016 μM (clorgyline), 
0.004 μM (harmaline), and 1.34 μM (toloxatone), respectively. 
Results obtained for harmaline and toloxatone were in good 
agreement with previous reports (Herraiz et al., 2010; Strolin 
Benedetti et al., 1983).
TABLE 1
MAO-A inhibition values of compounds
Compound IC
50
 (µM) K
i
 (µM)
K
i
 (µM) 
from IC
50
5-(2-Aminopropyl)indole (5-IT) 1.6 0.25 0.32
Clorgyline 0.016 — 0.016
Harmaline 0.020 — 0.004
Toloxatone 6.7 — 1.3
Moclobemide >500 — —
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I Discussion
The results indicate that 5-IT is an inhibitor of human MAO-A 
(K
i
 of 0.25 μM) (Table 1). Nevertheless, this value suggests 
that its potency as a MAO-A inhibitor is at least 10 times lower 
than that of clorgyline (i.e. K
i
 0.016 μM) that is an irreversible 
inhibitor of this enzyme. It is also lower than that of the 
β-carboline harmaline that is also a potent reversible inhibitor 
of MAO-A (IC
50
 of 1.6 μM for 5-IT vs. 0.020 μM for harmaline). 
However, 5-IT was apparently a more potent inhibitor in vitro 
than toloxatone and moclobemide. It is known that MAO-A 
inhibitors and antidepressants working as MAO inhibitors 
result in an increase of serotonin levels in vivo. It cannot be 
ruled out that recreational use of 5-IT could elevate serotonin 
levels by itself or in combination with other substances.
These results indicate that 5-IT is a highly selective inhibitor of 
MAO-A, which is a property also shared by α-methyl-
tryptamine (Tipton et al., 1982). Although the 5-IT structure 
contains a phenethylamine moiety it did not inhibit MAO-B. 
The ability of 5-IT to potentiate the hypertensive effects 
(‘cheese effect’) related to consumption of tyramine 
containing-foods cannot be fully excluded (Finberg & Gillman, 
2011).
In a previous report, Cerletti et al., (1968) studied the 
inhibition of MAO by 5-IT and its positional isomers. These 
authors reported a value of IC
50
 of 22 μM for 5-IT which was 
higher (i.e. less potent as an inhibitor) than the value reported 
here. Those differences might be attributed to the different 
assays as well as enzyme sources and fractions used. The 
assay of Cerletti et al., was based on the ability of guinea pig 
liver homogenate to uptake oxygen in an assay that used 
serotonin as the substrate of MAO, whereas recombinant 
human MAO enzymes and kynuramine deamination were 
used in the current study. In the same study, Cerletti et al. 
(1968) reported an antagonist effect of pentylenetetrazole/
reserpine (an antihypertensive drug) that might also be related 
to MAO inhibition. Previous results of Cerletti et al. (1968) and 
those reported here point to 5-IT as a selective inhibitor of 
MAO-A in the low micromolar range. Those results suggest 
that 5-IT by itself or in combination with other substances 
could potentiate serotonergic effects. However, further 
pharmacological and in vivo studies are needed to clarify this 
action and its relevance to the toxicological effects of 5-IT.
I Conclusions
The results from this study lead to the following conclusions 
concerning 5-(2-aminopropyl)indole (5-IT):
1.  5-IT is an inhibitor of MAO-A with an IC
50
 of 1.6 μM and K
i
 of 
0.25 μM. 
2.  5-IT is a reversible inhibitor of MAO-A. 
3.  5-IT is a competitive inhibitor of MAO-A. 
4.  5-IT is a highly selective inhibitor of MAO-A, and does not 
inhibit MAO-B. 
5.  Under the experimental conditions used here, other 
established inhibitors of MAO-A and antidepressants 
provided the following IC
50 
values: clorgyline 0.016 μM, 
harmaline 0.020 μM, toloxatone 6.7 μM and moclobemide 
>500 μM. In other words, 5-IT was less potent than 
clorgyline and harmaline and more potent than toloxatone 
and moclobemide. 
In summary, 5-IT is a relatively potent, reversible and selective 
inhibitor of MAO-A in vitro. In this regard it might increase 
monoamine levels, particularly serotonin. However, in order to 
clarify the significance of these results, further 
pharmacological and in vivo studies are needed to 
demonstrate MAO-A inhibition in vivo as well as an increase of 
serotonin and potential monoaminergic toxicity due to the use 
of 5-IT–containing drugs. 
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I Council Decision
Council Implementing Decision 2013/496/EU of 7 October 2013 on subjecting 
5-(2-aminopropyl)indole to control measures
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information 
exchange, risk-assessment and control of new psychoactive substances (1), and in 
particular Article 8(3) thereof,
Having regard to the proposal of the European Commission,
Whereas:
(1) A Risk Assessment Report on the new psychoactive substance 5-(2-aminopropyl)
indole was drawn up in accordance with Article 6 of Decision 2005/387/JHA by the 
extended Scientific Committee of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) during a special session, and was subsequently submitted to the 
Commission and to the Council on 16 April 2013.
(2) The substance 5-(2-aminopropyl)indole is a synthetic derivative of indole substituted at 
the phenyl side of the indole ring system. It appears to be a stimulant substance that may 
also have hallucinogenic effects. 5- (2-aminopropyl)indole has been found mostly in 
powder form but also in tablet and capsule form. It is commercially available on the 
internet and from ‘head shops’, marketed as a ‘research chemical’. It has also been 
detected in samples of a product sold as a ‘legal high’ called ‘Benzo Fury’, and in tablets 
resembling ecstasy.
(3) The existing information and data suggest that the acute toxicity of 5-(2-aminopropyl)
indole can provoke adverse effects in humans, such as tachycardia and hyperthermia, and 
may also cause mydriasis, agitation and tremor. 5-(2- aminopropyl)indole may interact with 
other substances, including medical products and stimulants that act on the 
monoaminergic system. The specific physical effects of 5-(2-aminopropyl)indole in 
humans are difficult to determine because there are no published studies assessing its 
acute and chronic toxicity, its psychological and behavioural effects, or dependence 
potential, and because of the limited information and data available.
(4) There have been a total of 24 fatalities registered in four Member States from April to 
August 2012, in relation to which 5-(2-aminopropyl)indole alone, or in combination with 
other substances, was detected in post-mortem samples. While it is not possible to 
determine with certainty the role of 5-(2-aminopropyl)indole in all of the fatalities, in some 
cases it has been specifically noted in the cause of death. If this new psychoactive 
substance were to become more widely available and used, the implications for individual 
and public health could be significant. There is no information available on the social risks 
posed by 5-(2-aminopropyl)indole.
(1) OJ L 127, 20.5.2005, p. 32.
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(5) Nine European countries have reported to the EMCDDA and to the European Police 
Office (Europol) that they reported detection of 5-(2-aminopropyl)indole. No prevalence 
data is available on the use of 5-(2-aminopropyl)indole, but the limited information that 
exists suggests that it may be consumed in similar environments as other stimulants, such 
as in the home, in bars and nightclubs or at music festivals.
(6) There is no information that suggests that 5-(2-aminopropyl)indole is manufactured in 
the Union, and there is no evidence suggesting the involvement of organised crime in the 
manufacture, distribution or supply of this new psychoactive substance.
(7) The substance 5-(2-aminopropyl)indole has no known, established or acknowledged 
medical value or use, and there is no marketing authorisation covering this new 
psychoactive substance in the Union. Apart from its use as an analytical reference 
standard and in scientific research, there is no indication that it is being used for other 
purposes.
(8) The substance 5-(2-aminopropyl)indole has not been, nor is it currently, under 
assessment by the United Nations system, as defined in Decision 2005/387/JHA. Two 
Member States control this new psychoactive substance under their national legislation by 
virtue of their obligations under the 1971 United Nations Convention on Psychotropic 
Substances. Five European countries apply national legislation on new psychoactive 
substances, dangerous goods or medicines to control 5-(2-aminopropyl)indole.
(9) The Risk Assessment Report reveals that there is limited scientific evidence available 
on 5-(2-aminopropyl)indole and points out that further research would be needed to 
determine the health and social risks that it poses. However, the available evidence and 
information provides sufficient ground for subjecting 5-(2-aminopropyl)indole to control 
measures across the Union. As a result of the health risks that it poses, as documented by 
its detection in several reported fatalities, of the fact that users may unknowingly consume 
it, and of the lack of medical value or use, 5-(2-aminopropyl)indole should be subjected to 
control measures across the Union. 
(10) Since six Member States already control 5-(2-aminopropyl)indole by means of 
different types of legislative provisions, subjecting this substance to control measures 
across the Union would help avoid the emergence of obstacles to cross-border law 
enforcement and judicial cooperation, and protect users from the risks that its 
consumption can pose. 
(11) Decision 2005/387/JHA reserves to the Council implementing powers to enable the 
provision of a quick, expertise-based response at Union level to the emergence of new 
psychoactive substances detected and reported by the Member States, by means of 
submitting those substances to control measures across the Union. As the conditions and 
procedure for triggering the exercise of such implementing powers have been met, an 
implementing decision should be adopted in order to put 5-(2-aminopropyl)indole under 
control across the Union, 
HAS ADOPTED THIS DECISION:
Article 1
The new psychoactive substance 5-(2-aminopropyl)indole is hereby subjected to control 
measures across the Union.
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Article 2 
By 13 October 2014, Member States shall take the necessary measures, in accordance 
with their national law, to subject 5-(2- aminopropyl)indole to control measures and 
criminal penalties, as provided for under their legislation complying with their obligations 
under the 1971 United Nations Convention on Psychotropic Substances. 
Article 3 
This Decision shall enter into force on the twentieth day following that of its publication in 
the Official Journal of the European Union. 
Done at Luxembourg, 7 October 2013. 
For the Council 
The President 
J. BERNATONISE
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Abbreviations
2-IT 2-(2-aminopropyl)indole
3-TFMPP 3-trifluoromethylphenylpiperazine
4-APB 4-(2-aminopropyl)benzofuran
5-APB 5-(2-aminopropyl)benzofuran
5-IT 5-(2-aminopropyl)indole 
6-APB 6-(2-aminopropyl)benzofuran
6-IT 6-(2-aminopropyl)indole
AM–2201 1-[(5-fluoropentyl)-1H-indol-3-yl]-(naphthalen-1-
yl)methanone
AMT alpha-methyltryptamine (3-(2-aminopropyl)
indole)
API active pharmaceutical ingredient
BZP 1-benzylpiperazine
CAS Chemical Abstracts Service
CI-MS chemical ionization mass spectrometry
D2PM diphenylprolinol (diphenyl(pyrrolidin-2-yl)
methanol)
Decision Council Decision 2005/387/JHA of 10 May 2005 
on the information exchange, risk assessment and 
control of new psychoactive substances
DAD diode array detector
ECHA European Chemicals Agency
EDND European Database on New Drugs
EI-MS electron ionization mass spectrometry
EMA European Medicines Agency 
EMCDDA European Monitoring Centre for Drugs and Drug 
Addiction
ENU Europol national units
ESI-MS/MS positive electrospray tandem mass spectrometry
EUR Euro
EWS early-warning system (EMCDDA–Europol)
GBP British pounds
GC gas chromatography
GC-IRD gas chromatography-infrared detection
GC-MS gas chromatography-mass spectrometry
GHB gamma-hydroxybutyrate
H-NMR proton nuclear magnetic resonance spectroscopy
IC
50
concentration of inhibitor that produces 50 % 
inhibition
Abbreviations
ICD International Classification of Diseases (WHO)
IUPAC International Union of Pure and Applied Chemistry
K
i
dissociation constant of the enzyme-inhibitor 
complex
K
m
Kinetic constant of Michaelis-Menten
LC liquid chromatography
LD
50
median lethal dose
MAO monoamine oxidase
MAO-A monoamine oxidase, isoenzyme A
MAO-B monoamine oxidase, isoenzyme B
MDA 3,4-methylenedioxyamphetamine
MDAI 5,6-methylenedioxy-2-aminoindane
MDMA 3,4-methylenedioxymethylamphetamine
MPA methylthienylpropamine
MRM multiple reaction monitoring
MS mass spectrometry
NFP national focal point of the Reitox network
NMR nuclear magnetic resonance spectroscopy
NMT N-methyltryptamine
NPIS National Poisons Information Service
pH negative logarithm of the concentration of 
hydronium ions in a solution
PMMA para-methoxymethamphetamine
REACH Regulation on Registration, Evaluation, 
Authorisation and Restriction of Chemicals
RP-HPLC-DAD reverse phase high-performance liquid 
chromatography coupled to diode array detector
SSRI selective serotonin reuptake inhibitor
THC tetrahydrocannabinol
TLC thin layer chromatography
UN United Nations
UPLC-TOF-MS ultra-performance liquid chromatography coupled 
to time-of-flight mass spectrometry
V
max
maximum velocity 
WHO World Health Organization
α-PVP alpha-pyrrolidinovalerophenone
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